1 Lifespan investigation of brain volumetric changes associated with substance use disorders

2

3 Author

Runye Shi¹, Shitong Xiang^{2,3}, Dag Alnæs^{4,5}, Di Chen^{2,6}, Zheng Chen², Tobias Banaschewski^{7,8}, Gareth J.
Barker⁹, Arun L.W. Bokde¹⁰, Sylvane Desrivières⁶, Herta Flor^{11,12}, Hugh Garavan¹³, Penny Gowland¹⁴,
Antoine Grigis¹⁵, Andreas Heinz¹⁶, Jean-Luc Martinot^{17,18}, Marie-Laure Paillère Martinot^{17,18,19}, Eric
Artiges^{17,18,20}, Frauke Nees^{7,8,21}, Dimitri Papadopoulos Orfanos¹², Luise Poustka²², Michael N. Smolka²³,
Sarah Hohmann^{7,8}, Nilakshi Vaidya²⁴, Henrik Walter¹⁶, Robert Whelan²⁵, Gunter Schumann^{23,26}, Barbara
J. Sahakian^{2,3,27}, Lars T. Westlye^{4,5}, Trevor W. Robbins^{2,3,28}, Xiaolei Lin^{1,29*}, Tianye Jia^{2,3,26,30,31*}, Jianfeng
Feng^{1,2,3,32,33,34*} and IMAGEN Consortium

12 Affiliations

- 13 ¹ School of Data Science, Fudan University, Shanghai, China
- 14 ² Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China
- 15 ³ Key Laboratory of Computational Neuroscience and Brain-Inspired Intelligence (Fudan University),
- 16 Ministry of Education, China
- 17 ⁴ Department of Psychology, University of Oslo, Oslo, Norway
- ⁵ Centre for Precision Psychiatry, Division of Mental Health and Addiction, Oslo University Hospital, Oslo,
- 19 Norway
- 20 ⁶ Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology &
- 21 Neuroscience, King's College London, London, United Kingdom
- ⁷ Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health,
- 23 Medical Faculty Mannheim, Heidelberg University, Square J5, 68159 Mannheim, Germany
- ⁸ German Center for Mental Health (DZPG), partner site Mannheim-Heidelberg-Ulm
- ⁹ Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College
- 26 London, United Kingdom
- ²⁷ ¹⁰ Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience, Trinity
- 28 College Dublin, Dublin, Ireland
- ¹¹ Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty
- 30 Mannheim, Heidelberg University, Square J5, Mannheim, Germany
- ¹² Department of Psychology, School of Social Sciences, University of Mannheim, 68131 Mannheim,
 Germany
- ¹³ Departments of Psychiatry and Psychology, University of Vermont, 05405 Burlington, Vermont, USA;
- ¹⁴ Sir Peter Mansfield Imaging Centre School of Physics and Astronomy, University of Nottingham,
- 35 University Park, Nottingham, United Kingdom
- 36 ¹⁵ NeuroSpin, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
- ¹⁶ Department of Psychiatry and Psychotherapy CCM, Charité Universitätsmedizin Berlin, corporate
- 38 member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin,
- 39 Germany
- 40 ¹⁷ Institut National de la Santé et de la Recherce Médicale, INSERM U A10 "Trajectoires
- 41 développementales & psychiatrie", University Paris-Saclay, Ecole Normale Supérieure Paris-Saclay,
- 42 CNRS
- 43 ¹⁸ Centre Borelli, Gif-sur-Yvette, France
- ⁴⁴ ¹⁹ AProHE: The property set of the second state of the seco

- 45 Hospital, Paris, France
- 46 ²⁰ Psychiatry Department, EPS Barthélémy Durand, Etampes, France
- 47 ²¹ Institute of Medical Psychology and Medical Sociology, University Medical Center Schleswig Holstein,
- 48 Kiel University, Kiel, Germany
- ²² Department of Child and Adolescent Psychiatry, Center for Psychosocial Medicine, University Hospital
 Heidelberg, Heidelberg, Germany
- 51 ²³ Department of Psychiatry and Psychotherapy, Technische Universität Dresden, Dresden, Germany
- 52 ²⁴ Centre for Population Neuroscience and Stratified Medicine (PONS), Department of Psychiatry and
- 53 Psychotherapy, Charité Universitätsmedizin Berlin, Germany
- ²⁵ School of Psychology and Global Brain Health Institute, Trinity College Dublin, Ireland;
- ²⁶ Centre for Population Neuroscience and Precision Medicine (PONS), Institute of Science and
- 56 Technology for Brain-Inspired Intelligence (ISTBI), Fudan University, Shanghai, China
- ²⁷ Department of Psychiatry, School of Clinical Medicine, Biomedical Campus, University of Cambridge,
- 58 Cambridge, United Kingdom
- 59 ²⁸ Department of Psychology and Behavioural and Clinical Neuroscience Institute, University of
- 60 Cambridge, Cambridge, United Kingdom
- ²⁹ Huashan Institute of Medicine, Huashan Hospital affiliated to Fudan University, Shanghai, China
- ³⁰ Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and
- 63 Neuroscience, King's College London, London, United Kingdom
- ³¹ School of Psychology, University of Southampton, Southampton, United Kingdom
- ³² MOE Frontiers Center for Brain Science, Fudan University, Shanghai, China
- 66 ³³ Zhangjiang Fudan International Innovation Center, Shanghai, China
- ³⁴ Department of Computer Science, University of Warwick, Coventry, United Kingdom
- 68 69

70 * Corresponding authors:

- Xiaolei Lin (Address: School of Data Science, Fudan University, Shanghai, 200433, China. Email:
 <u>xiaoleilin@fudan.edu.cn</u>)
- 73 or
- 74 Tianye Jia (Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai,
- 75 200433, China. Email: tianyejia@fudan.edu.cn)
- 76 or
- 77 Jianfeng Feng (Address: Institute of Science and Technology for Brain-inspired Intelligence, Fudan
- 78 University, Shanghai, 200433, China. Email: jianfeng64@gmail.com)

79 Abstract

Substance use disorder (SUD) stands as a critical public health concern, contributing to substantial 80 morbidity, mortality and societal costs. The effects of SUD on structural brain changes have been well 81 82 documented. However, the neural mechanisms underlying SUD and the spatial-temporal volumetric 83 changes associated with SUD remained underexplored. In this investigation, neuroimaging, behavioral and genomic data across four large population cohorts jointly covering the full lifespan were harmonized, 84 and whole-brain volumetric trajectories between substance use disorders (SUDs) and healthy controls 85 (HCs) were compared, revealing the potential neurobiological mechanisms and the genomic basis 86 87 underlying SUD. Results highlighted three distinct life stages critical for the development of SUD: 1) adolescence to early adulthood (before 25y), where SUD is suspected to be the consequence of prefrontal-88 subcortical imbalance during neurodevelopment; 2) early-to-mid adulthood (25y - 45y), where SUD was 89 90 strongly associated with compulsivity-related brain volumetric changes; 3) mid-to-late adulthood (after 45y), where SUD-related brain structural changes could be explained by neurotoxicity. Results were externally 91 validated both via longitudinal analysis of these population cohorts and in independent cross-sectional 92 samples. In summary, our study demonstrated the lifespan whole-brain volumetric changes associated 93 94 with SUD, revealed potential neurobehavioral mechanisms for the development of SUD, and suggested 95 critical time window for effective prevention and treatment of SUD.

96 Introduction

107

In recent years, there has been increasing research interest for human lifespan neuroscience, emphasizing 97 98 the challenges of understanding mental health and human behaviors associated with social and 99 physiological characteristics across different age stages¹. While most psychiatric disorders onset before 100 early adulthood², possibly partly attributed to puberty-related hormonal changes and unbalanced brain development³, they demonstrated distinct lifetime prevalence and longitudinal trajectories. Given these 101 102 complexities, understanding whether the neural signatures and behavioral profiles of different 103 neuropsychiatric disorders follow distinct developmental trajectories or represent a homogeneous 104 continuum remains an open question. Substance use disorder (SUD), which often emerges during 105 adolescence and persists across the entire lifespan, provides a unique case for investigating the lifespan 106 trajectories associated with brain volumetric changes and neurocognitive performances.

- 108 SUD is a complex health condition characterized by compulsive, persistent and risky substance use or 109 misuse behaviors in inappropriate situations⁴, exerting a lifespan impact on both mental and physical health⁵⁻⁷, including cognitive impairments, behavioral dysfunctions and chronic illnesses such as 110 111 cardiovascular disease and diabetes⁸⁻¹⁰. The high prevalence of SUD further amplifies its negative impacts. 112 In 2022, an estimated 17.3% (48.7 million) of the population aged 12 years or older in the United States 113 had SUD according to a self-reported national survey of approximately 70 thousand participants¹¹, 114 including 29.5 million having an alcohol use disorder, 27.2 million having drug use disorder, and 8.0 million 115 having both. In Europe, an estimated 29% (83.4 million) of those aged 15 years or older reported previous 116 use of illicit drugs¹². Some risk factors may exert different impacts at different life stages, with higher BMI positively correlated with alcohol consumption in adolescent girls^{13,14} and negatively associated with past-117 year alcohol abuse risk in adult women^{15,16}. Other factors were characterized by time-specific effects, for 118 119 example, the shift from an enriched to standard environment in mice was only found to enhance the 120 sensitivity of drug reward during early life stages¹⁷. Further, the progression of neuropsychiatric disorders 121 may vary across time with differential impacts on the brain, likely due to time-varying neuroplasticity and 122 long-term homeostatic compensation mechanisms taking place at different life stages^{18,19}. For instance, the risk of substance dependence is reduced by 4%–5% for each year of delayed substance use initiation 123 from age 13 to 21 years old when the brain gradually matures²⁰, while significantly increased in older life 124 125 stages with reduced drug metabolism and aging^{21,22}. Findings on longitudinal SUD-related changes in brain regions were inconsistent across studies, with some studies focusing on SUDs among adolescents, 126 while others specifically investigating early and mid-to-late adulthood²³⁻²⁷. Despite these insights, a 127 128 comprehensive lifespan approach on the neural mechanisms underlying SUD remains underexplored. 129
- 130 To address these questions, we utilized data from the Adolescent Brain Cognitive Development (ABCD) study²⁸, the IMAGEN study²⁹, the Human Connectome Project (HCP)³⁰ and UK Biobank (UKB)³¹ with 131 participants ranging from adolescence to early adulthood and extending into older ages. While previous 132 133 studies have revealed that both brain structures and functional connectivity undergo characteristic changes across the lifespan³²⁻³⁴, a normative model was introduced to deal with the heterogeneity within 134 population cohorts due to age and other study-specific characteristics, treating mental disorders and 135 specific behaviors as deviations from a normative developmental trajectory³⁵. Normative models were 136 137 constructed for each brain region of interest (ROI) using the Generalized Additive Model for Location, Scale 138 and Shape (GAMLSS)³⁶, which have demonstrable accuracy for depicting life-course trajectories of brain 139 morphology^{32,37}. Morphological characteristics were quantified as centile scores for all individuals to adjust

140 for potential confounding. Separate volumetric trajectories were constructed for individuals with SUD and healthy controls (HCs). In general, compared to HCs, individuals with SUD had lower grey matter volume 141 (GMV) in cortical regions, with differences following an inverted U-shape over time, while the GMV 142 143 differences in subcortical regions gradually decreased over time. Both volumetric and neurobehavioral 144 results were successfully validated using Enhanced Nathan Kline Institute-Rockland Sample (NKI-RS), 145 Cambridge Centre for Ageing and Neuroscience (Cam-CAN), and Brains and Minds in Transition 146 (BRAINMINT) samples. Correlations between GMV centiles and neurobehavioral scores were investigated 147 throughout the life span using common factors and pooled meta-analysis of effect sizes due to 148 inconsistencies in measurements across studies. Finally, to understand the genomic basis underlying the 149 lifespan SUD trajectories, genome-wide association study (GWAS) and genomic correlation analysis were 150 performed, and genetic variants associated with GMV-predicted SUD were identified using conjunctional 151 FDR³⁸ (conjFDR).

152 **Results**

153 Definition of SUD across the lifespan

154 A total of 51,467 participants aged 9y – 70y with 53,199 neuroimaging scans across four cohorts (ABCD, 155 IMAGEN, HCP and UKB) were included in the discovery set, and a total of 2,127 participants aged 12y -89y from the cross-sectional NKI-RS, Cam-CAN and BRAINMINT studies were included for validation. 156 157 Due to different accessibility of addictive substances used between adolescents and adults, an adaptive 158 definition of SUD (among alcohol, tobacco, marijuana and any other reported addictive substances) was 159 employed: for adolescents, those engaging in any addictive substances intake behavior or meeting the criteria of child addiction scale were classified as SUD; for adults, those meeting the clinical criteria of 160 161 substance dependence or ranking in the top 25% of substance use frequency were classified as SUD. 162 Meanwhile, participants with no substance use at any time throughout the life span or occasional 163 substance use during adulthood were considered as HCs. Detailed descriptions of the definitions of SUD 164 and HC were provided in the Methods section. Based on the criteria above, a total of 6,992 and 711 participants were identified as SUDs, while 18,659 and 1,416 were included as HCs in the discovery and 165 166 validation sets, respectively. Overall, the proportion of SUDs among the study population first increased 167 with age, peaked at approximately the age of 25y, and then started to decrease thereafter, as well as the 168 overlap of participants across different substance use groups. (Supplementary Fig. 1).

169

170 Cross-sectional investigation (Supplementary Table 1) indicated consistent differences between SUDs and HCs on demographic characteristics across the lifespan: SUDs are more likely to be males (X^2 = 8.80, P 171 = 0.003 for ABCD; X² = 5.29, P = 0.023 for IMAGEN-BL; X² = 39.53, P < 0.001 for IMAGEN-FU2; X² = 172 173 39.03, P < 0.001 for IMAGEN-FU3; $X^2 = 41.71$, P < 0.001 for HCP; $X^2 = 1248.3$, P < 0.001 for UKB), having 174 lower intelligence score (d = -0.40, P < 0.001 for ABCD; d = -0.20, P = 0.015 for IMAGEN-BL; d = -0.04, P 175 = 0.031 for UKB), residing in poorer socioeconomic conditions (d = -0.48, P < 0.001 for ABCD; d = -0.16, 176 P = 0.046 for IMAGEN-BL; d = -0.23, P = 0.002 for HCP; d = -0.27, P < 0.001 for UKB), and having 177 experienced more negative life events (d = 0.44, P < 0.001 for ABCD; d = 0.17, P = 0.009 for IMAGEN-FU2; d = 0.19, P = 0.010 for HCP; d = 0.22, P < 0.001 for UKB). On the contrary, we observed inconsistent 178 179 BMI between SUDs and HCs across different life stages: SUDs are more likely to be associated with larger 180 BMI during adolescence, but with lower BMI during late adulthood (d = 0.28, P = 0.011 for ABCD; d = 0.18, 181 *P* = 0.024 for IMAGEN-BL; *d* = 0.15, *P* = 0.025 for IMAGEN-FU2; *d* = -0.05, *P* = 0.005 for UKB).

182

183 Lifespan volumetric brain differences between SUDs and HCs

184 Twenty-four brain regions of interest (ROIs) involved in the development of SUD were selected as suggested by previous studies^{39,40}. These regions (ventral/dorsal striatum, amygdala, hippocampus, insula, 185 anterior cingulate and prefrontal cortex) are key components in the addiction neurocircuitry, and are 186 187 involved in reward processing, motivation, contextual memory, interoception, and executive function. The GAMLSS model³² was employed to harmonize neuroimaging data across the lifespan and construct age-188 189 specific normative ranges of HCs for each ROI (Supplementary Fig. 2). Cubic spline model was developed 190 to estimate the age-specific GMV trajectories for SUDs and HCs separately, adjusting for sex, handedness 191 and studies.

192

193 Dynamic GMV volumetric differences across the lifespan were observed between SUDs and HCs (Fig. 1). 194 During childhood and adolescence, compared to HCs, SUDs showed higher volumetric GMV in the 195 bilateral putamen and lower GMV in the bilateral nucleus accumbens, insula, frontal pole, orbitofrontal, 196 superior frontal, rostral anterior cingulate (ACC) and left caudal ACC. Notably, participants with SUD 197 experienced delayed development in the left medial orbitofrontal and bilateral nucleus accumbens, regions 198 that may mediate dopamine-related goal-directed behavior^{41,42}. This is also consistent with the finding that 199 smaller left ventral mediofrontal cortex was causally associated with smoking initiation among 200 adolescents²⁶. However, these GMV volumetric differences observed in early life stages gradually 201 diminished with brain development, which indicated that early brain volumetric differences between SUDs 202 and HCs could possibly contribute to the substance use. Later during adulthood, SUDs exhibited relatively 203 lower GMV and faster GMV decreasing rate in most ROIs. Starting from amygdala, GMV differences 204 between SUDs and HCs became increasingly apparent in the hippocampus, nucleus accumbens, medial 205 orbitofrontal cortex, and right lateral orbitofrontal cortex. involving hippocampus, nucleus accumbens, 206 medial orbitofrontal cortex and right lateral orbitofrontal cortex. Notably, higher volumetric GMV in SUDs 207 was also observed in the salience network (SN; also called mid-cingulo-insular network, including insula, 208 rostral ACC and left lateral orbitofrontal cortex), with significant differences starting at approximately 30y, 209 peaking at mid 40ys and gradually diminishing after 60y. According to the lifespan volumetric differences 210 between SUDs and HCs, ROIs can be subdivided into three categories: those differentiating SUDs and 211 HCs at early stages of life, including bilateral frontal pole, insula, orbitofrontal, superior frontal, rostral ACC, 212 nucleus accumbens and putamen; those differentiating SUDs and HCs at intermediate stages of life, 213 including bilateral insula, lateral orbitofrontal and rostral ACC; and those differentiating SUDs and HCs at 214 later stages of life, including left frontal pole, lateral orbitofrontal, bilateral medial orbitofrontal, superior 215 frontal, amygdala, hippocampus and nucleus accumbens.

216

217 The lifespan volumetric patterns between SUDs and HCs were validated via both longitudinal analysis of 218 the neuroimaging data using ABCD and UKB (Supplementary Fig. 3) and cross-sectional analysis of the 219 external NKI-RS, Cam-CAN and BRAINMINT datasets (Supplementary Fig. 4). Due to the limited sample 220 size and relatively large standard errors in validation samples, it was impractical to obtain statistically 221 significant results as in the discovery set. Therefore, the external validation largely relied on observing similar GMV volumetric patterns between SUDs and HCs, with moderate to strong correlations in 71% 222 223 significant comparative z-statistics (17 out of 24 ROIs; r = 0.25-0.95) between the discovery and validation 224 set.

225

226 Since the change of SUD definition from adolescence to adulthood may lead to the discontinuity of

volumetric GMV changes, a sensitivity analysis was conducted by modifying the SUD definition for adults
 such that those with above experimental substance use or regular substance use were also included as
 SUDs. Despite inconsistencies in certain ROIs, the overall lifespan GMV patterns between SUDs and HCs
 remain similar (Supplementary Fig. 5).

231

Although the lifespan volumetric patterns between SUDs and HCs were relatively consistent in the left and right hemispheres, we noticed that differences in the right hemisphere were more pronounced in putamen, frontal pole and lateral orbitofrontal regions compared to the left hemisphere, while differences in the left hemisphere were greater in the medial orbitofrontal and caudal ACC. These observed volumetric differences in the left and right hemispheres may suggest potential roles of the corresponding hemisphere during SUD development.

238

239 Further, we investigated the lifespan volumetric trajectories for SUDs separately for each addictive 240 substance, including alcohol, tobacco, marijuana and any other type of addictive drugs. The lifespan 241 volumetric differences between SUDs and HCs showed highly similar patterns for alcohol, tobacco and 242 marijuana (Supplementary Fig. 6-8), with slightly higher GMV in insula, rostral ACC and lateral orbitofrontal 243 observed for alcohol and marijuana users during early adulthood. However, inconsistent results were 244 observed for drug users, who showed higher GMV than HCs during late adulthood (Supplementary Fig. 245 9). This inconsistency was likely due to the small sample size and less robust model fitting of GMV 246 trajectories for drug users.

247

248 Lifespan associational patterns between neurobehavioral performances and SUD

249 Since SUD is often associated with neurobehavioral changes, we next investigated how this association 250 varies with age across lifespan by comparing SUD-related neurobehavioral performances between SUDs 251 and HCs in each study. Significant neurobehavioral differences in SUD emerge progressively over the life-252 course (Fig. 2A and Supplementary Tables 2-5). During pre-adulthood (in ABCD and IMAGEN studies), 253 SUDs were more likely to be engaged in rule-breaking behaviors, had more conduct problems and higher 254 impulsivity scores, especially in sensation seeking, based on self-reported questionnaires and cognitive 255 tests such as Monetary Incentive Delay task (MID) in ABCD and Monetary-Choice Test (KIRBY) in 256 IMAGEN. It is noteworthy that SUDs did not show preference for immediate rewards facing large delayed rewards in the KIRBY compared to HCs (d = 0.10, $P_{adj} = 0.154$), nor did they exhibit differences in reaction 257 time on the Stop Signal Task (SST) (d = -0.06, $P_{adj} = 0.363$), indicating that their impulsive behaviors were 258 259 relatively limited. We also found no evidence toward some aspects of impaired executive functioning 260 among SUDs via the Dimensional Change Card Sort Test in ABCD (cognitive flexibility) (d = -0.20, $P_{adj} =$ 0.072) and the spatial working memory test in IMAGEN (d = -0.07, $P_{adj} = 0.363$), although SUDs exhibited 261 lower fluid (d = -0.26, $P_{adj} = 0.028$) and crystallized cognitive abilities than HCs (d = -0.40, $P_{adj} = 6.51 \times 10^{-10}$ 262 263 ⁴). During early adulthood (in HCP study), SUDs started to show lower self-awareness, as measured by NIH Toolbox meaning and purpose in life (d = -0.31, $P_{adj} = 2.95 \times 10^{-4}$), and life satisfaction (d = -0.19, P_{adj} 264 = 0.032), while continued to have higher rule-breaking and impulsivity scores as measured by 265 266 questionnaires compared to HCs. They also display steeper delay discounting across all reward sizes, 267 including larger delayed rewards, suggesting potentially increased impulsivity for SUDs when transitioning 268 from adolescence to adulthood. Finally, during late adulthood (in UKB), SUDs exhibited both increased 269 mood problems and worse neurocognitive performances for executive functions compared to HCs. The 270 lifespan associational patterns between neurobehavioral performances and SUDs were partially validated

using the NKI-RS study with a broader age range (Supplementary Fig. 10), where we observed consistently higher rule-breaking and risk-taking scores for SUDs compared to HCs during both preadulthood and adulthood, with effect sizes decreasing over time.

274

275 Continuous SUD-related cognitive performances were derived from publicly available cognitive brain 276 atlases⁴³ across the lifespan, by correlating factor-level cognitive brain atlas with volumetric brain 277 differences between SUDs and HCs. Seven factors (working memory, emotion processing, reward 278 sensitivity, social cognition, general decision making, general cognitive impairment and inhibitory control, 279 and behavioral adaptation) were extracted from 133 cognitive terms, which explained 91% of the total 280 variances (Supplementary Table 6, Supplementary Fig. 11-12). Working memory, behavioral adaptation, 281 and reward sensitivity were primarily associated with SUD during early life stages. Specifically, the 282 prominent association between reward sensitivity and SUD in early adulthood aligned with our analytical 283 results using IMAGEN and HCP. In contrast, the general cognitive impairment and inhibitory control - SUD 284 association kept increasing and reached its peak during mid-to-late adulthood. This observed shift in the 285 cognitive profiles linked to SUD across the lifespan is consistent with the from-impulsivity-to-compulsivity 286 addiction hypothesis^{41,44}.

287

293

Nonetheless, it should be noted that despite progressively greater impulsivity found among SUDs in terms of fun seeking, sensation seeking and delay discounting, no significant differences were found between SUDs and HCs in terms of the Flanker inhibitory control and attention test. This suggests that when generalizing conclusions, one needs to consider issues such as different functionality of the composite dimension of impulsivity⁴⁵.

294 Having observed the lifespan associational patterns between neurobehavioral performances and SUDs, 295 we next explored the underlying neurobiological mechanisms via lifespan trajectories of volumetric GMV 296 (Fig. 3). Generalized rule-breaking and impulsivity scores were calculated by factor analysis to 297 accommodate for measurement variability across studies (Supplementary Fig. 13). Correlational analyses 298 between neurobehavioral performances and volumetric GMV were jointly conducted in pre-adulthood for 299 ABCD and IMAGEN, while separately in adulthood for HCP. Consistent with the volumetric patterns during 300 pre-adulthood, higher impulsivity was associated with higher volumetric GMV in dorsal striatum (bilateral 301 caudate and right putamen) and lower GMV in prefrontal (bilateral lateral orbitofrontal, frontal pole and left 302 medial orbitofrontal)/rostral ACC. Later in adulthood, higher impulsivity scores were associated with lower 303 GMV in bilateral caudate, frontal pole, lateral orbitofrontal, rostral ACC, right nucleus accumbens and left 304 medial orbitofrontal cortex. In contrast, significant negative correlation was observed between rule-305 breaking scores and GMV in rostral/dorsal striatum, prefrontal regions, and ACC during pre-adulthood, 306 with no significant correlations observed in adulthood. These results were robust when adjusting for rule-307 breaking scores between impulsivity and brain regions, and vice versa (Supplementary Fig. 14).

308

309 Longitudinal investigation of adolescent SUD development

While cross-sectional lifespan studies have provided valuable insights into SUD, understanding the early factors that contribute to substance use initiation in adolescence from a longitudinal perspective is also crucial for elucidating the mechanisms of SUD development in adolescence and informing prevention strategies. Thus, we investigate whether pre-adulthood volumetric differences could contribute to the initiation of substance use, along with any behavioral evidence. To test this, pre-adulthood HCs at baseline

315 were divided into two subgroups, with the first subgroup developing SUDs in the follow-up visits (hereafter 316 called follow-up SUDs) and the other subgroup remaining as HCs (hereafter called follow-up HCs). 1,930 out of 11,085 (17.41%) pre-adulthood HCs in ABCD and 549 out of 987 (55.62%) pre-adulthood HCs at 317 318 baseline in IMAGEN were identified as follow-up SUDs, respectively. In ABCD, follow-up SUDs tend to 319 have higher GMV in bilateral caudate (left: d = 0.05, $P_{adj} = 0.031$; right: d = 0.06, $P_{adj} = 0.018$) and putamen 320 (left: d = 0.05, $P_{adj} = 0.028$; right: d = 0.06, $P_{adj} = 0.018$), and lower GMV in left medial orbitofrontal (d = -321 0.06, $P_{adj} < 0.001$), right lateral orbitofrontal (d = -0.02, $P_{adj} = 0.045$), right frontal pole (d = -0.03, $P_{adj} = -0.03$, P_{a 0.046), bilateral rostral ACC (left: d = -0.05, $P_{adj} = 0.009$; right: d = -0.05, $P_{adj} = 0.018$) and caudal ACC 322 323 (left: d = -0.04, $P_{adj} = 0.009$; right: d = -0.04, $P_{adj} = 0.009$ (Supplementary Fig. 15). These results were 324 consistent with the volumetric differences between SUDs and HCs observed in the early-life stages, and 325 indicated an important role of the prefrontal-striatum imbalance in the onset of SUD. Due to smaller sample 326 size and potentially improvement of the prefrontal-striatum imbalance among adolescents, only lower 327 volumetric GMV in medial orbitofrontal was observed in the follow-up SUDs in IMAGEN (Supplementary 328 Fig. 10). Additionally, we examined whether resilience to pre-adulthood prefrontal-subcortical imbalance 329 may depend on the severity of SUD, and found no significant correlations between longitudinal GMV 330 changes and guantities of substance used or levels of substance dependency (Supplementary Table 7). 331 Regarding behavioral performance comparisons, follow-up SUDs exhibited higher total impulsivity score 332 and greater sensation seeking behaviors as measured by behavioral guestionnaires in both ABCD and 333 IMAGEN, whereas they also showed more conduct problems and rule-breaking tendencies in IMAGEN 334 (Supplementary Table 8). However, no differences in rule breaking behavior were observed between 335 follow-up SUDs and follow-up HCs in ABCD.

336

337 SUD-related genomics

338 To elucidate the genomic basis underlying the lifespan volumetric and neurobehavioral differences 339 between SUDs and HCs, we conducted a study-wise genome-wide association study (GWAS) 340 (Supplementary Fig. 16 and 17). Correlations between summary statistics from each study GWAS were 341 estimated and studies with closer age alignment of participants showed higher genetic correlations (Fig. 342 4A), suggesting a gradual transition of genomic contributions to SUD over time. When compared with 343 another published GWAS of SUD risk factors (Addiction risk factor; Addrf)^{46,47}, genetic correlations 344 between summary statistics in the corresponding GWAS were observed to increase with age and significant genetic correlation ($R^2 = 0.19$, $P = 7.16 \times 10^{-22}$) was obtained between the UKB GWAS and 345 346 published GWAS.

347

Next, a weighted-GMV (wGMV) score was calculated for each participant by weighing all ROI centiles with corresponding z-values obtained in the regional differential pattern for SUD (Fig. 4B), which represented one's probability of being SUD (versus HC). Significant wGMV differences were observed between SUDs and HCs in all studies except HCP (ABCD: d = 0.05, P = 0.041; IMAGEN: d = 0.11, P = 0.026; HCP: d =0.02, P = 0.196; UKB: d = 0.23, $P = 1.64 \times 10^{-28}$; one-sided t-test).

353

Finally, conjFDR was utilized to identify the localization of shared genetic variants between SUD and wGMV, localizing those specifically associated with SUD-related brain changes. At conjFDR < 0.05, five shared genetic loci were separately identified across the lifespan in ABCD, HCP and UKB/Addrf (Fig. 4C), whereas no significant locus was found in IMAGEN (Supplementary Fig. 18). During pre-adulthood (in ABCD), the shared locus rs11609619 on chromosome 12 was mapped to *CCDC91* and achieved

359 significantly higher polygenetic score (PGS) for CCDC91 expression in SUDs compared to HCs (d = -0.08, P = 0.007). CCDC91 has been reported to be involved in the development and maintenance of white 360 matter microstructure⁴⁸, an essential component of brain tissue for efficient neural communications⁴⁹ and 361 neurodevelopment⁵⁰. It was also found to be involved in several neurodevelopmental disorders in previous 362 363 studies⁵¹, indicating an important role of brain maturation in the initiation of SUD. During early-to-mid 364 adulthood (in HCP), three loci (rs10936851 on chromosome 3 mapping to PTPRD, rs9567983 on 365 chromosome 13 mapping to NUDT15, and rs6129798 on chromosome 20 mapping to ZHX3) were identified, with only rs10936851 achieving significantly higher PGS for PTPRD (d = 0.15, P = 0.046) in 366 SUDs, PTPRD is highly expressed in brain and works as a synaptic specifier and neuronal cell adhesion 367 molecule⁵². Previous studies have implicated its involvement in dopaminergic reward pathway and 368 369 increased vulnerability to substance addictiony^{53,54}. Finally, during mid-to-late adulthood (in UKB/Addrf), the shared locus rs10438244 on chromosome 14 was identified, which is a non-coding transcript variant 370 371 and was previously reported to be associated with alcoholism and tobacco use disorder⁵⁵. Although it has 372 been found to be associated with the expression of multiple genes⁵⁶ (i.e. *TDRD9*, *KLC1* and *COA8*), only significantly higher PGS for COA8 was observed in SUDs (d = -0.05, P = 0.011). COA8 (previously referred 373 374 to as APOPT1) plays critical role in the release of cytochrome c and protection against oxidative stress⁵⁷. and has been indicated in the development of a broad spectrum of psychiatric disorders^{58,59}. Combined 375 376 with the lifespan trajectory for the effects of these loci on SUD (Supplementary Fig. 19), these findings 377 suggest distinct genomic foundations for GMV-predicted SUD across different life stages.

378

To further examine the dynamic relationship between neurobiological markers and SUD-related volumetric differences, we performed a longitudinal association analysis leveraging the cortical gene expression atlas⁶⁰ (Fig. 4D), which provided 20 molecular- and cellular-level markers alongside one cortical microstructure marker. During early-to-mid adulthood, dopaminergic neurotransmitter (ni3-FDOPA-DAT-D1-NMDA) significantly explained the estimated SUD-HCs brain differences in cortical ROIs, with the strongest effect observed around 34y. This result is consistent with the mechanistic pathway we identified within similar age range using HCP.

386

387 Discussion

388 SUD has long been a critical public health issue due to its high prevalence and negative impacts on both 389 mental and physical health^{5,7,11,12}. Animal models and human studies have shown the importance of understanding the neurobiological mechanisms underlying the initiation and development of SUD^{40,61}. 390 391 However, due to the variability in brain morphology measurements and dynamic changes in volumetric 392 GMV during different life stages, age has long been suggested as a potential confounder in elucidating the 393 roles of neuroplasticity in SUD²³. Here, by harmonizing neuroimaging, neurobehavioral and genomic data 394 across multiple large population cohorts, we explored the lifespan trajectories of volumetric brain 395 morphology associated with SUD, SUD-related neurobehavioral performances, and its genetic basis. The 396 entire lifespan can be divided into three stages (Fig. 5): before 25y, where imbalanced regional brain 397 development lead to SUD and SUD-related impulsivity; 25y to 45y, with enlarged ROIs in salience network 398 and reinforcement of craving behaviors; after 45y, where SUD ultimately lead to widespread brain 399 volumetric reductions.

400

401 During pre-adulthood (from 8y to early 20s), individuals with SUD exhibited higher GMV in putamen, which

402 may imply a greater propensity to habit learning in SUDs⁴¹, and lower GMV in nucleus accumbens, ACC, superior frontal and prefrontal cortex. Similar volumetric GMV differences in these brain regions were 403 404 observed in participants with potential risk of developing follow-up SUD in the longitudinal analysis. Aligned 405 with previous studies²⁶, SUDs in IMAGEN only showed significantly decreased volumes in left medial 406 orbitofrontal, which is more restricted compared to the brain regions in younger cohorts. This is likely due 407 to the small sample size and SUD-associated neuroadaptations⁶² among IMAGEN adolescents. Our findings on brain regions with decreased SUD-related volumetric GMV (i.e. prefrontal, ACC and nucleus 408 409 accumbens) were consistent with previous research on adolescent substance use⁶³⁻⁶⁸, suggesting 410 important role of these ROIs on the development of adolescent SUD. However, although some studies 411 have demonstrated evidence of larger dorsal striatum volumes for SUDs during early-adulthood⁶⁹⁻⁷¹, few 412 studies exist for adolescents. Our results extended existing findings on SUD initiation in pre-adulthood, 413 and future research with larger sample sizes on adolescent SUD are required to provide further validation.

414

415 Combing the lifespan volumetric GMV and neurobehavioral patterns between SUDs and HCs, multiple 416 potential mechanisms could be inferred to contribute to the development of SUD during adolescence. 417 Firstly, developmental imbalance between dorsal striatum and prefrontal cortices was associated with impulsivity, which was also referred to as stopping impulsivity⁷², where dorsal striatum received extensive 418 dopaminergic innervation from substantia nigra⁷³ and were enlarged when the dopaminergic neurons are 419 420 over-expressed in the nigrostriatal pathway⁷⁴. It has been shown to be involved in a dopamine-related 421 impulsivity trait⁷⁵. This aligned with the findings from longitudinal analyses, indicating that impulsivity 422 precedes substance use initiation, suggesting a potential causal role. Additionally, lower volumetric 423 prefrontal cortices and ACC may be associated with lower top-down cognitive control, leading to increased rule-breaking behaviors during adolescence^{76,77}. Consistent with previous findings^{78,79}, our results 424 425 demonstrated negative correlations between nucleus accumbens/ventral striatum and rule-breaking 426 scores. This can be explained since nucleus accumbens receives projections from both the insula and the ventromedial prefrontal cortex⁸⁰, and rule-breaking was associated with decreased activation of insula 427 during reward anticipation⁷⁹. Ventral striatum also plays an important role in adjusting goal-directed 428 429 behavior based on predictions of future events, with action value signals broadcasted to prefrontal control 430 regions to guide decision making⁸¹. This process is especially critical during adolescence, a period characterized by changing environmental demands and a growing need for peer connection, making 431 432 adolescents particularly vulnerable to peer influence and subsequent substance use⁸²⁻⁸⁴. Taken together, 433 these findings, along with other research on diverse cognitive differences in adolescent alcohol misusers⁸⁵, 434 underscore the complex and multifaceted nature of SUD development in this critical developmental period. 435

In addition, our results revealed negative correlations between the dorsal striatum and rule-breaking behaviors. As impairments in putamen and caudate function have been reported to be associated with inferior performances of rule-based tasks^{86,87}, a possible explanation is that lower volumes of putamen and caudate lead to dysregulation of rule-based behavior. Our findings on the genomic basis of SUDrelated neurobehavioral changes also highlighted the importance of neurodevelopment, with gene *CCDC91* identified to be involved in the onset of neurodevelopmental disorders.

442

Significantly, brain volumetric differences between SUDs and HCs in pre-adulthood diminished when transitioning from late adolescence to early adulthood. Given that adolescence is a period characterized by morphological and functional transformations of the brain⁸⁸, we hypothesize that the diminishing

446 differences between SUDs and HCs could be explained by continued neurodevelopment or by compensatory adjustment of brain function. Longitudinal investigation suggested a potential mechanism 447 of imbalanced neurodevelopment in ROIs between subcortex and cortex for SUD. Therefore, the 448 449 resilience-like volumetric changes during early life stage could be explained either by the immature brain development in the absence of substance use⁸⁹, or neuroadaptations of the reward system in the presence 450 451 of substance use²⁰. Studies using rodent models demonstrated that enriched environment during 452 adolescence could reduce drug sensitivity in adulthood by decreasing the dopaminergic neurons in substantia nigra and activity of the hypothalamic-pituitary-adrenal axis⁹⁰⁻⁹⁴. This suggested a unique 453 454 adaptation of the brain to dopamine-induced behaviors in adolescence and a possible crucial interventional 455 window for SUDs before the age of 30.

457 Increased volumetric GMV was observed in SN for participants with SUD in early-to-mid adulthood, 458 specifically in rostral ACC, insula and lateral orbitofrontal. This network is known to be involved in emotion, 459 self-awareness, autonomics⁹⁵, and plays a role in mediating conscious emotion and interoception associated with addictive substances⁹⁶. The increased regional GMV of SN might be attributed to 460 hyperconnectivity within SN97,98 and enhanced craving behaviors99,100 associated with increased 461 dopaminergic activity¹⁰¹. However, some studies showed inconsistent results with decreased GMV of 462 463 insula and activation of multiple addiction associated tasks¹⁰², where inconsistency depend on the severity 464 and duration of SUD. Due to the negative effect of overactivation of SN on mood sensitivities¹⁰³, lower self-465 awareness and mood instability were observed. These factors are believed to contribute to the substance craving behaviors and self-administriation^{101,104}. Compared to the complex cognitive differences observed 466 467 in early adulthood SUD, only that factor encompassing general cognitive impairment, including inhibitory 468 control, and memory processes was linked to SUD in mid-to-late adulthood, as revealed by brain-informed 469 correlation analysis. Remarkably, these findings are the first to lend support from the perspective of 470 population analysis to the hypothesis that, as drug experience accumulates, the characteristics of drug use shifts from impulsive behaviors to compulsive behaviors^{41,44}. Alongside this, the more general 471 472 cognitive impairment in mid-to-late adulthood might be explained by the progressive expansion of drug-473 related brain activity from the ventromedial prefrontal regions toward more posterior and even temporal 474 regions¹⁰⁵, suggesting an important additional burden on the management of elderly drug users due to 475 general intellectual deterioration which will require additional rehabilitation.

477 Further, identification of a significant SUD-associated PTPRD locus suggested potential overactivation of 478 the dopaminergic reward pathway and enhanced values of additive substance cues. This result was also 479 supported by an age-related increase in the explained variance of a dopaminergic factor to the brain 480 change within the age range for HCP participants. Specifically, this factor was mainly composed of 481 dopamine precursors FDOPA, transporters DAT, D1 receptors enhancing drug-seeking behavior, and 482 NMDA receptors involved in habit formation. Therefore, early-to-mid adulthood can be characterized by 483 addiction development with positive feedback related to awareness/mood and reward system. It should be 484 noted that the volumetric differences between SUDs and HCs could only be observed for alcohol and 485 marijuana users, and future research of larger sample is called for smoking and intra-venous drug administration¹⁰⁶. 486

487

476

456

The SUD-associated volumetric changes of SN diminished during mid-to-late adulthood, which could be explained by decreased functional connectivity and activation among older adults^{107,108}, increased reward

threshold⁶², and potential neurotoxicity of the substances. This was subsequently supported by the findings 490 491 from the genetic analysis that significant SUD-associated locus COA8 was involved in the oxidative stress process. Brain regions with significant volumetric differences between SUDs and HCs emerge from 492 493 subcortex, amygdala, hippocampus, nucleus accumbens, extend to superior frontal and frontal pole cortex, 494 and finally to orbitofrontal cortex, naturally aligning with the timing of brain development and highlighting 495 the importance of neurodevelopment during the onset of SUD. Finally, the age-specific genetic correlations 496 across different studies additionally underscore the gradual evolving process of SUD-related mechanisms 497 from a genetic perspective.

498

Regarding hemispheric differences, although similar lifespan changes in both hemispheres were observed,
 regions related to top-down response inhibitory control appeared to be more pronounced in the right
 hemisphere.

502

503 While the homogeneity in the brain differential patterns across different substances was found, this was 504 not the case for participants with drug use disorder in the subgroup analysis, particularly in terms of late 505 adulthood. Despite the evidence that some types of drugs may cause gliosis, leading to larger regional 506 volumes^{109,110}, this result might arise from selection bias due to our exclusion criteria for participants with 507 neuropsychiatric disorders and a very small relative sample size in the drug use disorder in UKB.

508

509 To the best of our knowledge, this is the first study exploring the dynamics of SUD associated volumetric 510 trajectories across the lifespan. Our study demonstrated the importance of brain maturation in elucidating 511 the neurobiological mechanisms and genetic basis contributing to SUD. Nonetheless, there are several 512 limitations associated with this study. Firstly, due to limited accessibility of DSM assessment, definition of 513 SUD mostly depended on self-reported frequency and quantity of substance use. It should come to mind 514 that since ABCD does not include questions related to the substance use experience, the definition of SUD 515 has had to be relaxed to include substance misuse behaviors-that is, any over-early use of addictive 516 substances for participants. While this may seem to be a relatively broad definition, only 0.7% of individuals 517 in ABCD are identified as SUDs under this criterion. Secondly, although validated using longitudinal data, 518 the lifespan GMV trajectories for SUDs and HCs were estimated using cross-sectional data, with limited 519 sample sizes in childhood and mid-to-late adulthood. Further validations are needed for early adulthood, 520 where a noticeable shift of brain mechanisms could potentially occur. Cohorts with large sample sizes and 521 more detailed substance use data as well as actual clinical diagnosis are needed to validate the robustness 522 of our findings. Thirdly, different neurobehavioral measurements were adopted in different studies, which 523 could lead to bias in identifying brain regions associated with SUD. Although we tried to tackle this issue 524 by extracting common factors for rule-breaking behaviors and impulsivity across studies, consistent 525 neurobehavioral measurements are called for more accurate identification of consistent SUD-associated 526 brain regions. Fourthly, while previous studies have offered rationales for using cross-sectional brain atlases in longitudinal association analysis⁶⁰, bias is inevitable, particularly for age-sensitive research. 527 Finally, caution should be taken when interpretating consistently higher impulsivity among SUD 528 529 participants, mostly in self-reported measures. Given that impulsivity is considered a broad and 530 multifaceted concept, different test results may convey different messages. Future research on multi-531 ancestry comparisons is also called for more generalized conclusions.

- 532
- 533

534 Methods

535 Ethical statement

536 All cohort data used in this study comply with relevant ethical regulations and informed consent was sought 537 from all participants and a parent/guardian of each participant if under 18 years in all studies. ABCD and 538 HCP study was supported by the National Institutes of Health (NIH). The IMAGEN study was approved by 539 local ethnical research committees at each research site: King's College London, University of Nottingham, 540 Trinity College Dublin, University of Heidelberg, Technische Universitat Dresden, Commissariat a l'Energie 541 Atomique et aux Energies Alternatives, and University Medical Center. UK Biobank has approval from the 542 North West Multi-centre Research Ethics Committee as a Research Tissue Bank approval. NKI-RS 543 received approvals from the Nathan Kline Institute and Montclair State University. Cam-CAN was approved 544 by the local ethics committee, Cambridgeshire 2 Research Ethics Committee and BRAINMINT was 545 approved by the Regional Committee for Medical and Health Research Ethics South-Eastern Norway.

546 Participants

Participants from four large population cohorts (ABCD, IMAGEN, HCP and UKB) were harmonized to estimate the lifespan trajectories of volumetric GMV for SUDs and HCs in the discovery set, and those from NKI-RS and Cam-CAN were harmonized similarly for external validation except BRAINMINT. In all studies, participants with both non-missing neuroimaging and substance use data were included, and those with any serious medical or neurological conditions, pre-existing psychiatric or neuropsychiatric disorders other than SUD, other illnesses that could confound neuroimaging, or with GMV beyond 4 interquartile ranges in any ROI were excluded.

554 ABCD is a longitudinal neuroimaging cohort with 11,875 adolescents from 21 sites across the United 555 States enrolling at baseline. The version 3.0 (baseline; 9-10 years old) and 4.0 (follow-up; 11-13 years old) 556 of the annual curated data releases for ABCD (https://abcdstudy.org/about/) were used in this analysis. At 557 baseline, a total of 11,301 participants (52.2% males) consisting of 11,217 HCs and 84 SUDs were included, 558 with 7,775 having follow-up imaging visits. IMAGEN is a multicenter neuroimaging longitudinal cohort, where approximately 2,000 healthy adolescents of European descent across multiple sites in Europe were 559 560 recruited at baseline (age 14y) and multiple follow-up visits at 16y (FU1), 19y (FU2) and 23y (FU3). A total 561 of 1.504 participants (53.7% males) with 1.298 HCs and 185 SUDs at baseline, 539 HCs and 419 SUDs 562 at FU2, and 345 HCs and 450 SUDs at FU3 were included in this analysis, with average number of MRI 563 scans per participant being 2.15. HCP is a cross-sectional cohort of healthy young adult aged 22y - 37yand a total of 1,113 participants (45.6% males) with 396 HCs and 310 SUDs were included in this analysis. 564 565 UKB is an ongoing population cohort with over 500.000 participants aged 37v - 73v recruited in 2006-566 2010, where follow-up neuroimaging assessments were applied to a subset of participants from 2014 to 2019. A total of 37,549 participants (47.3% males), with 6,243 HCs and 5,897 SUDs at baseline and 914 567 568 HCs and 328 SUDs at follow-up visits were included in the analysis. NKI-RS is an ongoing cross-sectional cohort of adults in Rockland County¹¹¹, and a total of 1,112 participants (37.6% males) aged 12y – 80y 569 570 with 862 HCs and 250 SUDs were included for external validation. Cam-CAN is a cross-sectional project 571 designed to explore healthy aging, with 700 participants in UK aged 12y - 89y examined for brain structure measures¹¹², and a total of 445 participants (49.0% males) with 140 HCs and 305 SUDs were included for 572 573 validation. The BRAINMINT study is a longitudinal study investigating the mechanisms of brain plasticity 574 involving children and adolescents aged 9y - 25y from Oslo in Norway. Only cross-sectional data from 570 575 participants (28.4% males) were included for the validation analysis, comprising 414 HCs and 156 SUDs. 576 Detailed descriptions of population characteristics for studies were provided in the Supplementary Tables

577 1 and 9.

578 Assessment of substance use

579 Due to the varying accessibility of addictive substances for participants in different life stages, different 580 standards were used to identify participants with SUD and HC. For ABCD, according to the self-reported 581 substance use interview records, SUD was defined as participants with: 1) any full drink of beer, wine or 582 liquor; 2) more than just a puff of cigarette, electronic cigarette, "chew", cigar, hookah, pipes, and nicotine 583 replacement; 3) more than just a puff of marijuana-included products and fake marijuana; and 4) any try 584 of stimulants, depressants, hallucinogens and inhalants, and HC was defined as those with no use of any 585 addictive substance. For IMAGEN, SUD was defined as participants with: 1) child Alcohol Use Disorders Identification Test (AUDIT) total score > 7; 2) Fagerstrom Test for Nicotine Dependence (FTND) score >= 586 587 1; 3) any try of marijuana (grass, pot) or hashish for participants at baseline / > 10 times for participants at 588 follow-ups; and 4) any try of stimulants, depressants hallucinogens and inhalants, and HC was defined as 589 those with no exposure to any addictive substance. The frequency and quantity of substance use was 590 measured by European School Survey Project on Alcohol and Drugs (ESPAD) questionnaire. For HCP, 591 SUD was defined as participants with: 1) DSM-4 criteria for alcohol abuse or alcohol dependence met; 2) 592 FTND score \geq 4; 3) DSM-4 criteria for marijuana dependence met; and 4) any use of illicit drugs > 10 times, 593 and HC was defined as those meeting all of the following requirements: 1) no DSM-4 alcohol dependence 594 or abuse symptoms endorsed; 2) no smoking history or only experimental uses; 3) no marijuana used ever; 4) no use of illicit drugs ever. For UKB, SUD was defined as participants with: 1) weekly alcohol 595 596 assumption > 15 units and alcohol use almost daily; 2) current smokers on most or all days; 3) cannabis 597 ever taken > 100 times; and 4) ever addicted to illicit or recreational drugs, and HC was defined as those 598 meeting all of the following requirements: 1) less than weekly use of alcohol; 2) no current and past 599 smoking; 3) no marijuana use; 4) never addicted to illicit or recreational drugs. For NKI-RS, SUD was 600 defined as participants with: 1) any use of tobacco, alcohol, marijuana and additive drugs (age<18); 2) 601 clinical diagnosis of substance abuse or dependency in DSM-IV (age≥18), and HC was defined as those 602 not meeting the criteria of SUD. For Cam-CAN, SUD was defined as participants with: 1) weekly alcohol 603 use \geq 3 or 4 times; 2) current smoking; 3) intermediate or substantial drug use severity, and HC was defined 604 as those meeting all of the following requirements: 1) monthly alcohol use < 4 times or less or past drinker; 605 2) total smoking quantity < 100 or past smoker; 3) no drug used ever. For BRAINMINT, substance use 606 behaviors were measured using CRAFFT+N questionnaire. SUD was defined as participants with any use 607 of full drink containing alcohol, tobacco-related products, marijuana or anything else to get high in past 608 year and CRAFFT score >= 2, and HC was defined as those not meeting the criteria of SUD.

In sensitivity analysis, we tested whether the discontinuity of brain volumetric differences between SUDs
 and HCs from pre-adulthood to adulthood could be attributed to the change of SUD/HC definition.
 Definitions of SUD and HC were modified by replacing all above defined HCs in HCP and UKB as mild
 SUDs.

613 Assessment of behavioral and neurocognitive performances

Neurobehavioral measurements were selected according to potential circuits associated with SUD^{39,40}. In ABCD, rule breaking and conduct problem scores from Child Behavior Check List (CBCL), "fun seeking" score from Behavioral inhibition and Behavioral Activations scales (BIS/BAS), total impulsivity score from the UPPS-P Impulsive Behavior Scale, Flanker Inhibitory Control and Attention Test (Flanker) and Stop Signal Test (SST) were used for the measurement of rule-breaking behaviors and impulsivity. The accuracy rates of small reward trials and large reward trials adjusted the accuracy in neural trials from Monetary 620 Incentive Delay task (MID) were used to measure reward sensitivity. The Dimensional Change Card Sort 621 Test (DCCS) score was used to measure the cognitive flexibility aspect of executive function. In IMAGEN, 622 conduct problem score from Strengths and Difficulties Questionnaire (SDQ), novelty seeking personality 623 score from Temperament and Character Inventory (TCI), average sensation seeking and impulsivity scores 624 from Substance Use Risk Profile Scale (SURPS) as well as Monetary-Choice Questionnaire (KIRBY) were 625 used for the measurement of rule-breaking behaviors and impulsivity. The CANTAB Spatial Working 626 Memory (SWM) test was used to measure working memory components of executive function¹¹³. In HCP, 627 rule breaking score from Achenbach Adult Self Report (ASR), conduct problem score from Semi-Structured 628 Assessment for the Genetics of Alcoholism (SSAGA). Flanker test as well as delayed discounting task 629 were used to measure rule-breaking behaviors and impulsivity. The index in discounting task is the Area 630 Under the Curve for Discounting of different delayed reward vary in \$200 and \$4K. A smaller AUC indicates 631 steep delay discounting, i.e., increased preference toward short-term benefits. DCCS was used for the 632 measurement of executive function. We also included emotional measurements offered by NIH Toolbox, 633 where participants were asked to evaluate their life experiences in terms of life satisfaction, meaning and 634 purpose, and perceived stress. In UKB, the only question about rule-breaking is whether people treated 635 themselves as a risk-taking person. Other measurements for psychological well-being included mood 636 swing, irritability, fed-up feelings, anhedonia feeling and life satisfaction for individuals. Executive function 637 was measured by numeric short-term memory task and tower rearranging test. In NKI-RS, the health 638 subscale risk taking score from the Domain-Specific Risk-Taking Scale (DOSPERT), rule-breaking 639 behavior score from youth/adult self-report (YSR/ASR), sensation seeking score from UPPS-P Impulsive 640 Behavior Scale, impulsivity score from parent-rated Conners ADHD Rating Scale (Conner-P) and Conners 641 Adult ADHD Rating Scale (CAARS), social awareness score from Social Responsiveness Scale (SRS), 642 executive functioning score from Conner-P and conflict effect score from Attention Network Test (ANT) 643 were used. Self-esteem score was calculated as the sum of the 7th, 8th and 14th term in Beck Depression 644 Inventory (BDI) questionnaire.

645 Assessment of adverse childhood experience

646 The total childhood trauma experiences score was calculated as the number of reported events at initial 647 measurements across emotional neglect, physical neglect, emotional abuse, physical abuse and sexual 648 abuse subscales. In ABCD, emotion neglect from Children's Report of Parental Behavioral Inventory 649 (focused on the first caregiver; ≥2 matching descriptions), physical neglect from Parent Monitoring Survey 650 (focused on the first three personal safety questions; ≥ 1 matching descriptions), abuse (764-765 for 651 emotional abuse; 761-763 for physical abuse; 767-769 for sexual abuse) from Parent Diagnostic Interview 652 for DSM-5 (KSADS) Traumatic Events - post-traumatic stress disorder module (≥1 matching descriptions) were obtained as suggested¹¹⁴. In IMAGEN, all subscales were obtained from Childhood Trauma 653 Questionnaire (CTQ) with pre-defined cut-off values¹¹⁵. 654

655 Acquisition, imputation and quality control of genomic data

For ABCD, the genotype data were obtained directly from the public release 3.0, and imputed using the Michigan Imputation Server with hrc.r1.1.2016 reference panel¹¹⁶ and Eagle v2.3 phasing. Due to genetic diversity85 and low linkage disequilibrium (LD) levels of African populations86, a total of 2,387 ABCD subjects self-reporting ancestral origins as Black or African American was excluded. One participant per family was randomly selected to avoid within family correlations. For IMAGEN, details of the genotyping and quality control could be found in Desrivières et al¹¹⁷, imputed using the TOPMed imputation server with the HapMap3 reference panel¹¹⁸. For HCP, detailed genotyping and quality control could be found

in¹¹⁹, where imputation was performed with the 1000 Genomes panel¹²⁰. For UKB, detailed genotyping 663 and quality control procedures are available in¹²¹. Individuals that were estimated to have recent British 664 ancestry and have no more than ten putative third-degree relatives in the kinship table were included. 665 666 Similar quality control standards were performed by PLINK 1.90 across studies. Individuals with >10% 667 missing rate and single-nucleotide polymorphisms (SNPs) with call rates < 95%, minor allele frequency < 668 1%, deviation from the Hardy-Weinberg equilibrium with P < 1E-10 were excluded from the analysis. Thus, 669 a total of 7,662 participants and 5,020,358 SNPs in ABCD, 1,982 participants and 5,966,316 SNPs in IMAGEN, 897 participants and 5,375003 SNPs in HCP, and 337,151 participants and 8,894,431 SNPs in 670 671 UKB were included in the genomic analysis.

672 Acquisition and preprocessing of neuroimaging data

673 Neuroimaging data in ABCD were obtained using 3T scanners (Siemens Prisma, General Electric MR750 674 and Philips Achieva dStream) with 32-channel head coil and high resolution T1-weighted structural MRI. 675 The pre-processing processes and quality control procedures were completed by the ABCD research teams according to the ABCD standard pipeline and protocol^{122,123}. Neuroimaging data in IMAGEN were 676 obtained using 3T MRI systems based on the ADNI protocol from 4 different manufacturers (Siemens 677 678 Philips, GE Healthcare, and Bruker), with detailed MR protocols and QC procedures described in¹²⁴. In 679 HCP, neuroimaging data were obtained on a Siemens Skyra 3T scanner employing a 32-channel head 680 coil with protocols provided in https://www.humanconnectome.org. In UKB, neuroimaging data were 681 obtained with a standard Siemens Skyra 3T scanner with a 32-channel head coil, identical in both hardware 682 and software in Manchester, Newcastle, and Reading. Details of preprocessing and QC processes could 683 be found in¹²⁵. In brief, quality-controlled processed T1-weighted neuroimaging data were obtained directly 684 from cohort teams. The NKI-RS neuroimaging data were obtained following the same protocols as HCP 685 provided by the University of Minnesota. Quality controlled T1 images were downloaded. The Cam-CAN 686 neuroimaging data were provided by the University of Cambridge using the same MRC CBU scanner 687 according to¹²⁶. The BRAINMINT neuroimaging data were obtained using a 3T GE SIGNA Premier scanner 688 with a 48-channel head coil. Then regional volumes were extracted by FreeSurfer v6.0 (BRAINMINT 689 processed by v7.3.2) cross-sectional pipelines using Desikan-Killiany (h.aparc) atlas for cortical regions, 690 and ASEG atlas for subcortical regions, except for UKB, where Brain volumetric phenotypes could be 691 acquired directly by category ID 192&190. Quality check was performed according to FreeSurfer 692 reconstruction quality-controlled (QC) measures.

693 Harmonization of neuroimaging data across multiple cohorts via GAMLSS

694 Motivated by the use of GAMLSS model in construction of brain charts³², normative model was used to 695 harmonize neuroimaging data across multiple study cohorts. ComBAT method was first employed to 696 remove confounding due to imaging scanners within each study (ComBat function in sva-3.46.6 package). 697 For Cam-CAN, due to a change in the scanner coil during data collection and differences in MTI TR across 698 participants, these two confounding variables were also preemptively corrected using ComBAT. Next, 699 regional GMV was modeled using a generalized gamma distribution, with mean and variance defining 700 functions involving fractional polynomials of age, sex, handedness and study-specific random effects 701 (gamlss-5.4.18 package)³². The number of fractional polynomials and whether to include a study random 702 effect was determined for each ROI based on Bayesian information criterion (BIC) (Supplementary Fig. 2). 703 The same optimal GAMLSS models were also applied during the validation phase. Only cross-sectional 704 HCs were used for model fitting, including baseline ABCD data, sampled IMAGEN data, HCP data and 705 baseline UKB data. A single observation was randomly sampled from all visits among IMAGEN Individuals

with more than one neuroimaging scans, with sampling probability being standardized reciprocal of the
 distribution frequency. Finally, volumetric characteristics for each participant were placed on the normative
 model to obtain age- and sex-specific centiles.

709 Estimation of the lifespan volumetric GMV trajectories for SUDs and HCs

710 Since GAMLSS does not provide standard error estimates, generative additive model (GAM) was used to 711 compare mean regional GMV across different ages between SUDs and HCs. First, confounding effects 712 due to sex, handedness and study on the GMV measures were removed, and covariate-adjusted GMV 713 were obtained, with the underlying assumption that effects of these confounders on GMV were 714 independent of substance use status. Next, lifespan GMV trajectories across age were constructed 715 separately for SUDs and HCs using GAM (gam function in mgcv-1.9.0). Cubic spline with K=3 was used 716 as the basis function for age (spline-4.2.2). To obtain continuous comparisons of the age-dependent GMV 717 trajectories between SUDs and HCs, we began by predicting the mean and standard error estimated from 718 group-level GMV trajectories at discrete ages between 8y and 70y with a step of 0.05y. Two-sided z test 719 was used to test the null hypothesis that population GMV in SUDs and HCs was identical. After correcting 720 for multiple comparisons via False Discovery Rate (FDR) method, GAM with cubic spline basis were 721 selected to construct continuous significance comparisons between SUDs and HCs across the lifespan. 722 Then, we explored whether there was heterogeneity in brain differential patterns for SUDs from two 723 aspects. On one hand, SUDs were divided into four groups with different substance use behaviors, 724 including alcohol, tobacco, marijuana and any other type of addictive drugs. Lifespan volumetric patterns 725 were estimated separately for these four groups and compared with HCs. On the other hand, hierarchical 726 clustering method was used for individual GMV centiles to investigate potential clustering characteristics 727 in changing patterns between brain regions for SUD.

728 Validation of the lifespan volumetric GMV trajectories for SUDs and HCs

729 The lifespan brain differential trajectories for SUD were validated in two ways. Firstly, validation was 730 performed using the longitudinal ABCD and UKB datasets, where the baseline data overlapped with the 731 training data. Individual longitudinal volumetric changes were calculated as the difference in GMV between 732 follow-up and baseline. The change rate in SUD relative to HC was obtained using the linear regression 733 model adjusting for age and sex. The magnitude and direction of change rates for ROIs were compared 734 with the estimated slope differences at the corresponding individual ages using fitted GAM models. 735 following the same estimation process and parameter settings as mentioned above. Second, external NKI-736 RS and Cam-CAN datasets were harmonized following the same estimation process and parameter 737 settings as mentioned in the discovery analysis above, resulting in an independent normative model for 738 the entire validation phase. Since the BRAINMINT samples could only be analyzed on a local server, an 739 inverse-variance weighted meta-analysis was conducted to combine the HC and SUD change trajectories 740 from BRAINMINT with those derived from NKI-RS and Cam-CAN samples in overlapping ages. Then two-741 sided z tests at different time points and GAM with cubic spline basis were used to refit the differential 742 trajectories similarly. As it is hard to obtain statistically significant results in the validation sets due to limited 743 samples, spearman correlation analysis was used to assess the consistency of differential patterns in the 744 discovery and validation datasets.

745 Comparison of lifespan neurobehavioral performances between SUDs and HCs

Two-sided t-test was used to compare neurobehavioral measurements between SUDs and HCs in the discovery phase. In ABCD, we also applied down-sampling methods to address the severe class imbalance problem in SUD. A linear interaction term between age and SUD was included to evaluate the

749 time-varying neurobehavioral changes in SUDs in external validation, with age, SUD, sex, handedness 750 included as covariates. Standard error was calculated assuming multivariate normal distribution. Factor 751 analysis was applied to calculate composite scores for rule-breaking and impulsivity due to heterogeneity 752 of measurement tools (Supplementary Fig. 13). As there is only one self-reported question about risk-753 taking personal characteristics related to rule-breaking or impulsivity in UKB, it is not included in the brain-754 neurobehavior correlational analysis. The number of common factors were determined by the number of 755 eigen values larger than 1. Correlations between the extracted factors and GMV centiles of each ROI were 756 calculated for all studies. BH-FDR method was used for multiple testing. To highlight the impact of lifespan brain-neurobehavior correlations, effect sizes were meta-analyzed within studies of adolescents (ABCD 757 and IMAGEN), whereas HCP was only used as the resource of adult study. Since rule-breaking and 758 impulsivity are mildly correlated in ABCD (r = 0.08, $P_{adi} = 1.47 \times 10^{-12}$), we adjusted for rule-breaking score 759 760 in the correlational analysis between impulsivity and brain GMV, and vice versa as a sensitivity analysis.

761 Longitudinal association analysis using brain atlases

762 Cognitive term based meta-analysis statistical brain atlases⁴³ were downloaded from Neurosynth⁴³ (https://neurosynth.org/) and parcellated according to the APARC and ASEG atlases using NiMARE 763 0.0.11^{127,128}. Factor analysis with varimax rotation was then used. All factors explaining > 1% of the 764 765 variance were kept, resulting in seven factors. To ensure that these factors were highly representative of 766 underlying cognitive processes, only cognitive terms with loadings > 0.2 and also within the top 50^{th} 767 percentiles were retained for each factor. Factor loadings and factor-level brain atlases are available in the 768 Supplementary Fig. 11-12. Subsequently, univariate correlation analyses were performed between the 769 factor-level cognitive brain atlases and differential z-statistic of ROIs between SUD and HC at 0.5y intervals 770 from 8y to 70y. Explained variance (R^2) was calculated to represent the influential levels, and P-values 771 were determined using 1000 spin permutations. BH-FDR method was used for multiple testing within each 772 ROI. A similar analysis was conducted using neurobiomarker brain atlases⁶⁰, where 20 molecular- and 773 cellular-level factors were obtained along with one cortical microstructure factor from cortical gene 774 expression atlases, limiting the analysis to cortical region of interest. P-values were also calculated via 775 1000 permutations and adjusted for multiple testing by BH-FDR method, with null maps generated according to⁶⁰. 776

777 GWAS, genetic correlation analysis and conjFDR

778 Scalable and accurate Implementation of generalized mixed model⁵⁵ (SAIGE) was used for genetic 779 associations to avoid inflating Type I error due to case-control imbalance, and P values were obtained via 780 saddlepoint approximation. Given the longitudinal nature of ABCD and IMAGEN, participants were defined 781 as cases when they can be classified as SUDs for more than the average times of the total visits. This 782 resulted in 6,177 cases (SUDs) and 1,485 controls (HCs) in ABCD, and 605 cases and 1377 controls in 783 IMAGEN, respectively. To better understand how estimated GMV trajectories may contribute to the 784 development of SUD, we calculated a wGMV score, representing the possibility of being classified as SUD 785 using GMV. This score was composed of all ROI centiles weighted by the z-value obtained in the GWAS 786 comparing SUDs and HCs. When wGMV was used as the continuous phenotype, GWAS was conducted 787 using Plink 2.0, with sex, handedness, age at baseline, self-reported ethnicity, and the top k population 788 genetic principal components (k = 20 for ABCD and k = 10 for the other three studies) included as covariates. Within-sibship GWAS¹²⁹ was used for both binary and continuous phenotype GWAS for HCP. 789 790 A published GWAS of SUD risk factors^{46,47} (Addrf) was used as a reference to assess the consistency of 791 our GWAS results, where cross-trait polygenic risk score was calculated and used to evaluate genetic

correlations between summary statistics of the published GWAS and SUD GWAS. Specifically, the published GWAS was used as the testing sample and PGS was calculated on the testing sample after LDbased pruning (window size=50kb, variant count=5 and R^2 threshold=0.1) using the GWAS summary statistics from the current GWAS in Plink 1.90, adjusting for sex, handedness, age, self-reported ethnicity, and population genetic principal components. Estimated genetic correlations were then corrected using *bcPRS* function in R¹³⁰.

Finally, ConjFDR¹³¹ was used to identify specific shared genetic variants between SUD and wGMV. Test statistic for the SNP effects on SUD is re-ranked based on their associational strength with wGMV, obtaining the conditional FDR value. The maximal conditional FDR value was selected as the conjFDR value. We also investigated common genetic variants shared between wGMV in UKB and the SUD risk factor with the study population primarily consisting of individuals in mid-to-late adulthood. As no significant results were found between SUD and wGMV in UKB (Supplementary Fig. 18), we instead reported the conjFDR results between SUD in UKB and the SUD risk factor.

Genetic variants identified in the above analysis were mapped to genes using Open Targets Genetics (<u>www.opentargets.org</u>), which integrates evidence from molecular phenotype quantitative trait loci, chromatin interaction, in silico functional predictions and distance between the variant and the canonical transcript start site of genes. To further prove the effects of specific genes on SUD, we calculated PGS for both RNA expression and protein level of corresponding genes based on publicly available GWAS summary statistics¹³². Two-sided t-test was used to compare the PGS between SUDs and HCs.

811

812 Data Availability

813 The raw ABCD, IMAGEN, HCP, UKB, NKI-RS, Cam-CAN and BRAINMINT data are protected and are not 814 available due to data usage agreement. However, access can be obtained upon application except 815 BRAINMINT samples, which could only be analyzed on local server in the University of Oslo. ABCD data 816 can be accessed at https://abcdstudy.org/; IMAGEN data can be accessed by email at https://imagen-817 project.org/; HCP data are available from: https://www.humanconnectome.org/; UKB data can be accessed 818 at https://biobank.ndph.ox.ac.uk/; NKI-RS data can be applied by mail; and Cam-CAN data can be 819 accessed from: http://www.mrc-cbu.cam.ac.uk/datasets/camcan/. Cognitive term and factor-level gene 820 expression brain atlases can be accessed at https://neurosynth.org/ and 821 https://github.com/LeonDLotter/CTdev/. Published GWAS summary statistics of SUD risk factor (Addrf) 822 can be accessed by mail from⁴⁶. Publicly available GWAS summary statistics for multi-omics traits can be 823 accessed at https://www.omicspred.org/.

824

825 Code Availability

826 Primary analyses were conducted in R v4.2.2 and atlas-related analysis were conducted in Python 3.9.10. 827 GAMLSS models were performed using gamlss-5.4.18 and gamlss.dist 6.1-1 R packages. GAM models 828 were built using mgcv 1.9.0 R package. NiMARE 0.0.11 was used to download and process Neurosynth 829 atlases. SAIGE was used to perform GWAS (https://github.com/saigegit/SAIGE) and genetic correlation 830 was calculated following codes from https://github.com/xm1701/bcPRS?tab=readme-ov-file using Plink 831 1.90 and bcPRS 0.0.0.9000 R package. ConjFDR was used to identify genetic loci shared between two 832 phenotypes (https://github.com/precimed/pleiofdr). Open Targets Genetics was used to perform functional 833 annotations (www.opentargets.org).

834

835 **References**

- Walhovd, K. B., Lovden, M. & Fjell, A. M. Timing of lifespan influences on brain and cognition. *Trends Cogn Sci* 27, 901-915, doi:10.1016/j.tics.2023.07.001 (2023).
- 8382Solmi, M. *et al.* Age at onset of mental disorders worldwide: large-scale meta-analysis of 192839epidemiological studies. *Mol Psychiatry* 27, 281-295, doi:10.1038/s41380-021-01161-7 (2022).
- Sturman, D. A. & Moghaddam, B. The neurobiology of adolescence: changes in brain architecture,
 functional dynamics, and behavioral tendencies. *Neurosci Biobehav Rev* 35, 1704-1712,
 doi:10.1016/j.neubiorev.2011.04.003 (2011).
- McLellan, A. T. Substance Misuse and Substance use Disorders: Why do they Matter in Healthcare? *Trans Am Clin Climatol Assoc* 128, 112-130 (2017).
- 8455Volkow, N. D., Koob, G. F. & McLellan, A. T. Neurobiologic Advances from the Brain Disease Model of846Addiction. N Engl J Med 374, 363-371, doi:10.1056/NEJMra1511480 (2016).
- Formanek, T., Krupchanka, D., Mlada, K., Winkler, P. & Jones, P. B. Mortality and life-years lost following
 subsequent physical comorbidity in people with pre-existing substance use disorders: a national
 registry-based retrospective cohort study of hospitalised individuals in Czechia. *Lancet Psychiatry* 9,
 957-968, doi:10.1016/S2215-0366(22)00335-2 (2022).
- 7 Joutsa, J. *et al.* Brain lesions disrupting addiction map to a common human brain circuit. *Nat Med* 28,
 1249-1255, doi:10.1038/s41591-022-01834-y (2022).
- 853 8 Steinfeld, M. R. & Torregrossa, M. M. Consequences of adolescent drug use. *Transl Psychiatry* 13, 313,
 854 doi:10.1038/s41398-023-02590-4 (2023).
- 855 9 Eddie, D., Greene, M. C., White, W. L. & Kelly, J. F. Medical Burden of Disease Among Individuals in
 856 Recovery From Alcohol and Other Drug Problems in the United States: Findings From the National
 857 Recovery Survey. *J Addict Med* 13, 385-395, doi:10.1097/ADM.00000000000512 (2019).
- 85810Dickey, B., Normand, S. L., Weiss, R. D., Drake, R. E. & Azeni, H. Medical morbidity, mental illness,859and substance use disorders. *Psychiatr Serv* **53**, 861-867, doi:10.1176/appi.ps.53.7.861 (2002).
- 86011Substance Abuse and Mental Health Services Administration. Key substance use and mental health861indicators in the United States: Results from the 2022 National Survey on Drug Use and Health (HHS862Publication No. PEP23-07-01-006, NSDUH Series H-58). Center for Behavioral Health Statistics and863Quality, Substance Abuse and Mental Health Services Administration (2023).
- 86412European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2022: Trends and865Developments. Publications Office of the European Union (2022).
- 86613Lanza, H. I., Grella, C. E. & Chung, P. J. Adolescent obesity and future substance use: Incorporating867the psychosocial context. *J Adolesc* **45**, 20-30, doi:10.1016/j.adolescence.2015.08.014 (2015).
- Weichold, K., Wiesner, M. F. & Silbereisen, R. K. Childhood predictors and mid-adolescent correlates
 of developmental trajectories of alcohol use among male and female youth. *J Youth Adolesc* 43, 698716, doi:10.1007/s10964-013-0014-6 (2014).
- Barry, D. & Petry, N. M. Associations between body mass index and substance use disorders differ by
 gender: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Addict Behav* 34, 51-60, doi:10.1016/j.addbeh.2008.08.008 (2009).
- Liu, S., Serdula, M. K., Williamson, D. F., Mokdad, A. H. & Byers, T. A prospective study of alcohol intake
 and change in body weight among US adults. *Am J Epidemiol* 140, 912-920,
 doi:10.1093/oxfordjournals.aje.a117179 (1994).

- Nader, J. *et al.* Loss of environmental enrichment increases vulnerability to cocaine addiction.
 Neuropsychopharmacology 37, 1579-1587, doi:10.1038/npp.2012.2 (2012).
- 18 Marin, O. Developmental timing and critical windows for the treatment of psychiatric disorders. *Nat Med*880 22, 1229-1238, doi:10.1038/nm.4225 (2016).
- Hubener, M. & Bonhoeffer, T. Neuronal plasticity: beyond the critical period. *Cell* **159**, 727-737,
 doi:10.1016/j.cell.2014.10.035 (2014).
- Jordan, C. J. & Andersen, S. L. Sensitive periods of substance abuse: Early risk for the transition to
 dependence. *Dev Cogn Neurosci* 25, 29-44, doi:10.1016/j.dcn.2016.10.004 (2017).
- Koechl, B., Unger, A. & Fischer, G. Age-related aspects of addiction. *Gerontology* 58, 540-544,
 doi:10.1159/000339095 (2012).
- 22 Dowling, G. J., Weiss, S. R. & Condon, T. P. Drugs of abuse and the aging brain.
 Neuropsychopharmacology 33, 209-218, doi:10.1038/sj.npp.1301412 (2008).
- Pando-Naude, V. *et al.* Gray and white matter morphology in substance use disorders: a neuroimaging
 systematic review and meta-analysis. *Transl Psychiatry* **11**, 29, doi:10.1038/s41398-020-01128-2
 (2021).
- Mackey, S. *et al.* Mega-Analysis of Gray Matter Volume in Substance Dependence: General and
 Substance-Specific Regional Effects. *Am J Psychiatry* **176**, 119-128,
 doi:10.1176/appi.ajp.2018.17040415 (2019).
- 89525Winters, K. C., Tanner-Smith, E. E., Bresani, E. & Meyers, K. Current advances in the treatment of896adolescent drug use. Adolesc Health Med Ther 5, 199-210, doi:10.2147/AHMT.S48053 (2014).
- Xiang, S. *et al.* Association between vmPFC gray matter volume and smoking initiation in adolescents. *Nat Commun* 14, 4684, doi:10.1038/s41467-023-40079-2 (2023).
- 899 27 Glisky, E. L. in *Brain Aging: Models, Methods, and Mechanisms Frontiers in Neuroscience* (ed D. R.
 900 Riddle) (2007).
- 8 Karcher, N. R. & Barch, D. M. The ABCD study: understanding the development of risk for mental and
 902 physical health outcomes. *Neuropsychopharmacology* 46, 131-142, doi:10.1038/s41386-020-0736-6
 903 (2021).
- 90429Mascarell Maricic, L. *et al.* The IMAGEN study: a decade of imaging genetics in adolescents. *Mol*905*Psychiatry* 25, 2648-2671, doi:10.1038/s41380-020-0822-5 (2020).
- 30 Van Essen, D. C. *et al.* The Human Connectome Project: a data acquisition perspective. *Neuroimage*907 62, 2222-2231, doi:10.1016/j.neuroimage.2012.02.018 (2012).
- 90831Sudlow, C. *et al.* UK biobank: an open access resource for identifying the causes of a wide range of909complex diseases of middle and old age. *PLoS Med* **12**, e1001779, doi:10.1371/journal.pmed.1001779910(2015).
- 91132Bethlehem, R. A. I. *et al.* Brain charts for the human lifespan. *Nature* **604**, 525-533, doi:10.1038/s41586-912022-04554-y (2022).
- 91333Luo, N. *et al.* Age-related structural and functional variations in 5,967 individuals across the adult914lifespan. *Hum Brain Mapp* **41**, 1725-1737, doi:10.1002/hbm.24905 (2020).
- 91534Yang, Z. *et al.* Connectivity trajectory across lifespan differentiates the precuneus from the default916network. *Neuroimage* **89**, 45-56, doi:10.1016/j.neuroimage.2013.10.039 (2014).
- 91735Marquand, A. F. *et al.* Conceptualizing mental disorders as deviations from normative functioning. *Mol*918*Psychiatry* 24, 1415-1424, doi:10.1038/s41380-019-0441-1 (2019).
- 91936Stasinopoulos, M. D., Kneib, T., Klein, N., Mayr, A. & Heller, G. Z. Generalized additive models for920location, scale, and shape : a distributional regression approach, with applications. First edition. edn,

921 (Cambridge University Press, 2024). 922 37 Di Biase, M. A. et al. Mapping human brain charts cross-sectionally and longitudinally. Proc Natl Acad 923 Sci U S A 120, e2216798120, doi:10.1073/pnas.2216798120 (2023). 924 Smeland, O. B. et al. Discovery of shared genomic loci using the conditional false discovery rate 38 925 approach. Hum Genet 139, 85-94, doi:10.1007/s00439-019-02060-2 (2020). 926 39 Everitt, B. J. & Robbins, T. W. Neural systems of reinforcement for drug addiction: from actions to habits 927 to compulsion. Nat Neurosci 8, 1481-1489, doi:10.1038/nn1579 (2005). 928 40 Koob, G. F. & Volkow, N. D. Neurocircuitry of addiction. Neuropsychopharmacology 35, 217-238, 929 doi:10.1038/npp.2009.110 (2010). 930 Everitt, B. J. & Robbins, T. W. Drug Addiction: Updating Actions to Habits to Compulsions Ten Years On. 41 931 Annu Rev Psychol 67, 23-50, doi:10.1146/annurev-psych-122414-033457 (2016). 932 42 Ersche, K. D. et al. Brain networks underlying vulnerability and resilience to drug addiction. Proc Natl 933 Acad Sci U S A 117, 15253-15261, doi:10.1073/pnas.2002509117 (2020). 934 Yarkoni, T., Poldrack, R. A., Nichols, T. E., Van Essen, D. C. & Wager, T. D. Large-scale automated 43 935 synthesis of human functional neuroimaging data. Nat Methods 8, 665-670, doi:10.1038/nmeth.1635 936 (2011). 937 44 Belin, D., Mar, A. C., Dalley, J. W., Robbins, T. W. & Everitt, B. J. High impulsivity predicts the switch to 938 compulsive cocaine-taking. Science 320, 1352-1355, doi:10.1126/science.1158136 (2008). 939 45 Dalley, J. W. & Robbins, T. W. Fractionating impulsivity: neuropsychiatric implications. Nat Rev Neurosci 940 18, 158-171, doi:10.1038/nrn.2017.8 (2017). Hatoum, A. S. et al. The addiction risk factor: A unitary genetic vulnerability characterizes substance 941 46 942 use disorders and their associations with common correlates. Neuropsychopharmacology 47, 1739-943 1745, doi:10.1038/s41386-021-01209-w (2022). 944 47 Hatoum, A. S. et al. Multivariate genome-wide association meta-analysis of over 1 million subjects 945 identifies loci underlying multiple substance use disorders. Nat Ment Health 1, 210-223, 946 doi:10.1038/s44220-023-00034-y (2023). 947 48 Sprooten, E. et al. Common genetic variants and gene expression associated with white matter 948 microstructure in the human brain. Neuroimage 97, 252-261, doi:10.1016/j.neuroimage.2014.04.021 949 (2014). 950 49 Dean, D. C., 3rd et al. Mapping White Matter Microstructure in the One Month Human Brain. Sci Rep 951 7, 9759, doi:10.1038/s41598-017-09915-6 (2017). 952 Lebel, C. & Deoni, S. The development of brain white matter microstructure. Neuroimage 182, 207-218, 50 953 doi:10.1016/j.neuroimage.2017.12.097 (2018). 954 51 Gonzalez-Mantilla, A. J., Moreno-De-Luca, A., Ledbetter, D. H. & Martin, C. L. A Cross-Disorder Method 955 to Identify Novel Candidate Genes for Developmental Brain Disorders. JAMA Psychiatry 73, 275-283, 956 doi:10.1001/jamapsychiatry.2015.2692 (2016). 957 Uhl, G. R. & Martinez, M. J. PTPRD: neurobiology, genetics, and initial pharmacology of a pleiotropic 52 958 contributor to brain phenotypes. Ann N Y Acad Sci 1451, 112-129, doi:10.1111/nyas.14002 (2019). 959 Uhl, G. R. et al. Cocaine reward is reduced by decreased expression of receptor-type protein tyrosine 53 960 phosphatase D (PTPRD) and by a novel PTPRD antagonist. Proc Natl Acad Sci U S A 115, 11597-961 11602, doi:10.1073/pnas.1720446115 (2018). 962 54 Ho, E. V., Welch, A., Thompson, S. L., Knowles, J. A. & Dulawa, S. C. Mice lacking Ptprd exhibit deficits in goal-directed behavior and female-specific impairments in sensorimotor gating. PLoS One 18, 963 964 e0277446, doi:10.1371/journal.pone.0277446 (2023).

- S5 Zhou, W. *et al.* Efficiently controlling for case-control imbalance and sample relatedness in large-scale
 genetic association studies. *Nat Genet* 50, 1335-1341, doi:10.1038/s41588-018-0184-y (2018).
- 967 56 Consortium, G. T. The GTEx Consortium atlas of genetic regulatory effects across human tissues.
 968 Science 369, 1318-1330, doi:10.1126/science.aaz1776 (2020).
- Signes, A. *et al.* APOPT1/COA8 assists COX assembly and is oppositely regulated by UPS and ROS. *EMBO Mol Med* 11, doi:10.15252/emmm.201809582 (2019).
- 971 Cross-Disorder Group of the Psychiatric Genomics Consortium. Electronic address, p. m. h. e. & Cross-58 972 Disorder Group of the Psychiatric Genomics, C. Genomic Relationships, Novel Loci, and Pleiotropic 973 **Mechanisms** across Eiaht **Psychiatric** Disorders. Cell 179. 1469-1482 e1411. 974 doi:10.1016/j.cell.2019.11.020 (2019).
- 97559Ma, L., Shcherbina, A. & Chetty, S. Variations and expression features of CYP2D6 contribute to976schizophrenia risk. *Mol Psychiatry* **26**, 2605-2615, doi:10.1038/s41380-020-0675-y (2021).
- 97760Lotter, L. D. *et al.* Regional patterns of human cortex development correlate with underlying978neurobiology. Nat Commun 15, 7987, doi:10.1038/s41467-024-52366-7 (2024).
- Feltenstein, M. W. & See, R. E. The neurocircuitry of addiction: an overview. *Br J Pharmacol* 154, 261 274, doi:10.1038/bjp.2008.51 (2008).
- Volkow, N. D., Michaelides, M. & Baler, R. The Neuroscience of Drug Reward and Addiction. *Physiol Rev* 99, 2115-2140, doi:10.1152/physrev.00014.2018 (2019).
- 63 Cheetham, A. *et al.* Volumetric differences in the anterior cingulate cortex prospectively predict alcohol984 related problems in adolescence. *Psychopharmacology (Berl)* 231, 1731-1742, doi:10.1007/s00213985 014-3483-8 (2014).
- 98664Whittle, S. *et al.* Structural brain development and depression onset during adolescence: a prospective987Iongitudinal study. *Am J Psychiatry* **171**, 564-571, doi:10.1176/appi.ajp.2013.13070920 (2014).
- 988 65 Squeglia, L. M. *et al.* Brain volume reductions in adolescent heavy drinkers. *Dev Cogn Neurosci* 9, 117989 125, doi:10.1016/j.dcn.2014.02.005 (2014).
- 99066Cheetham, A. *et al.* Orbitofrontal volumes in early adolescence predict initiation of cannabis use: a 4-991yearlongitudinalandprospectivestudy.*BiolPsychiatry***71**,684-692,992doi:10.1016/j.biopsych.2011.10.029 (2012).
- 99367Urosevic, S. *et al.* Effects of reward sensitivity and regional brain volumes on substance use initiation994in adolescence. Soc Cogn Affect Neurosci 10, 106-113, doi:10.1093/scan/nsu022 (2015).
- Jones, S. A., Morales, A. M., Lavine, J. B. & Nagel, B. J. Convergent neurobiological predictors of
 emergent psychopathology during adolescence. *Birth Defects Res* 109, 1613-1622,
 doi:10.1002/bdr2.1176 (2017).
- 99869Wetherill, R. R. *et al.* Cannabis, Cigarettes, and Their Co-Occurring Use: Disentangling Differences in999Gray Matter Volume. Int J Neuropsychopharmacol 18, pyv061, doi:10.1093/ijnp/pyv061 (2015).
- 100070Ersche, K. D. *et al.* Abnormal brain structure implicated in stimulant drug addiction. Science 335, 601-1001604, doi:10.1126/science.1214463 (2012).
- 1002 71 Bohbot, V. D., Del Balso, D., Conrad, K., Konishi, K. & Leyton, M. Caudate nucleus-dependent
 1003 navigational strategies are associated with increased use of addictive drugs. *Hippocampus* 23, 9731004 984, doi:10.1002/hipo.22187 (2013).
- 100572Dalley, J. W., Everitt, B. J. & Robbins, T. W. Impulsivity, compulsivity, and top-down cognitive control.1006Neuron 69, 680-694, doi:10.1016/j.neuron.2011.01.020 (2011).
- 1007
 73
 Haber,
 S.
 N.
 Corticostriatal
 circuitry.
 Dialogues
 Clin
 Neurosci
 18,
 7-21,

 1008
 doi:10.31887/DCNS.2016.18.1/shaber (2016).

 </

- 1009 74 Luo, X., Mao, Q., Shi, J., Wang, X. & Li, C. R. Putamen gray matter volumes in neuropsychiatric and
 1010 neurodegenerative disorders. *World J Psychiatry Ment Health Res* 3 (2019).
- 1011 75 Buckholtz, J. W. *et al.* Dopaminergic network differences in human impulsivity. *Science* 329, 532,
 1012 doi:10.1126/science.1185778 (2010).
- 101376Liston, C. *et al.* Frontostriatal microstructure modulates efficient recruitment of cognitive control. *Cereb*1014*Cortex* 16, 553-560, doi:10.1093/cercor/bhj003 (2006).
- 1015 77 Nagy, Z., Westerberg, H. & Klingberg, T. Maturation of white matter is associated with the development 1016 cognitive childhood. of functions during J Cogn Neurosci 16, 1227-1233, 1017 doi:10.1162/0898929041920441 (2004).
- 1018 78 Urosevic, S., Collins, P., Muetzel, R., Lim, K. O. & Luciana, M. Pubertal status associations with reward
 1019 and threat sensitivities and subcortical brain volumes during adolescence. *Brain Cogn* 89, 15-26,
 1020 doi:10.1016/j.bandc.2014.01.007 (2014).
- 102179Schneider, S. *et al.* Risk taking and the adolescent reward system: a potential common link to substance1022abuse. Am J Psychiatry 169, 39-46, doi:10.1176/appi.ajp.2011.11030489 (2012).
- Haber, S. N. & Knutson, B. The reward circuit: linking primate anatomy and human imaging.
 Neuropsychopharmacology **35**, 4-26, doi:10.1038/npp.2009.129 (2010).
- 102581Lourenco, F. & Casey, B. J. Adjusting behavior to changing environmental demands with development.1026Neurosci Biobehav Rev 37, 2233-2242, doi:10.1016/j.neubiorev.2013.03.003 (2013).
- 102782Hall, J. A. & Valente, T. W. Adolescent smoking networks: the effects of influence and selection on future1028smoking. Addict Behav 32, 3054-3059, doi:10.1016/j.addbeh.2007.04.008 (2007).
- Liu, M., Zhao, W. Q., Zhao, Q. R., Wang, Y. & Li, S. G. The impact of the peer effect on adolescent
 drinking behavior: instrumental-variable evidence from China. *Front Psychiatry* 14, 1306220,
 doi:10.3389/fpsyt.2023.1306220 (2023).
- 103284Reed, M. D. & Rountree, P. W. Peer pressure and adolescent substance use. Journal of Quantitative1033Criminology 13, 143-180, doi:10.1007/BF02221306 (1997).
- 1034 85 Whelan, R. *et al.* Neuropsychosocial profiles of current and future adolescent alcohol misusers. *Nature*1035 512, 185-189, doi:10.1038/nature13402 (2014).
- 103686Ell, S. W., Marchant, N. L. & Ivry, R. B. Focal putamen lesions impair learning in rule-based, but not1037information-integrationcategorizationtasks.Neuropsychologia44,1737-1751,1038doi:10.1016/j.neuropsychologia.2006.03.018 (2006).
- 103987Seger, C. A. & Cincotta, C. M. The roles of the caudate nucleus in human classification learning. J1040Neurosci 25, 2941-2951, doi:10.1523/JNEUROSCI.3401-04.2005 (2005).
- 104188Spear,L.P.Adolescentneurodevelopment.JAdolescHealth52,S7-13,1042doi:10.1016/j.jadohealth.2012.05.006 (2013).
- 104389Konrad, K., Firk, C. & Uhlhaas, P. J. Brain development during adolescence: neuroscientific insights1044into this developmental period. Dtsch Arztebl Int 110, 425-431, doi:10.3238/arztebl.2013.0425 (2013).
- 104590Solinas, M., Thiriet, N., El Rawas, R., Lardeux, V. & Jaber, M. Environmental enrichment during early1046stages of life reduces the behavioral, neurochemical, and molecular effects of cocaine.1047Neuropsychopharmacology 34, 1102-1111, doi:10.1038/npp.2008.51 (2009).
- 1048 91 Zakharova, E., Miller, J., Unterwald, E., Wade, D. & Izenwasser, S. Social and physical environment
 1049 alter cocaine conditioned place preference and dopaminergic markers in adolescent male rats.
 1050 *Neuroscience* 163, 890-897, doi:10.1016/j.neuroscience.2009.06.068 (2009).
- 105192Beckmann, J. S. & Bardo, M. T. Environmental enrichment reduces attribution of incentive salience to1052a food-associated stimulus. *Behav Brain Res* 226, 331-334, doi:10.1016/j.bbr.2011.09.021 (2012).

- 105393Cain, M. E., Green, T. A. & Bardo, M. T. Environmental enrichment decreases responding for visual1054novelty. *Behav Processes* **73**, 360-366, doi:10.1016/j.beproc.2006.08.007 (2006).
- 105594Bezard, E. *et al.* Enriched environment confers resistance to 1-methyl-4-phenyl-1,2,3,6-1056tetrahydropyridine and cocaine: involvement of dopamine transporter and trophic factors. *J Neurosci*105723, 10999-11007, doi:10.1523/JNEUROSCI.23-35-10999.2003 (2003).
- 105895Seeley, W. W. The Salience Network: A Neural System for Perceiving and Responding to Homeostatic1059Demands. J Neurosci 39, 9878-9882, doi:10.1523/JNEUROSCI.1138-17.2019 (2019).
- 1060
 96
 Naqvi, N. H. & Bechara, A. The hidden island of addiction: the insula. *Trends Neurosci* **32**, 56-67,

 1061
 doi:10.1016/j.tins.2008.09.009 (2009).
- 1062 97 Claus, E. D., Blaine, S. K., Filbey, F. M., Mayer, A. R. & Hutchison, K. E. Association between nicotine
 1063 dependence severity, BOLD response to smoking cues, and functional connectivity.
 1064 *Neuropsychopharmacology* 38, 2363-2372, doi:10.1038/npp.2013.134 (2013).
- 106598Naqvi, N. H., Gaznick, N., Tranel, D. & Bechara, A. The insula: a critical neural substrate for craving1066and drug seeking under conflict and risk. Ann N YAcad Sci **1316**, 53-70, doi:10.1111/nyas.12415 (2014).
- 106799Qi, C. *et al.* Structural Imaging-Based Biomarkers for Detecting Craving and Predicting Relapse in1068SubjectsWithMethamphetamineDependence.FrontPsychiatry11, 599099,1069doi:10.3389/fpsyt.2020.599099 (2020).
- 1070 100 Chen, Y., Chaudhary, S., Wang, W. & Li, C. R. Gray matter volumes of the insula and anterior cingulate 1071 dysfunctional roles Addict cortex and their in cigarette smoking. Neurosci 1. 1072 doi:10.1016/j.addicn.2021.100003 (2022).
- 1073101Volkow, N. D., Wang, G. J., Fowler, J. S. & Tomasi, D. Addiction circuitry in the human brain. Annu Rev1074Pharmacol Toxicol 52, 321-336, doi:10.1146/annurev-pharmtox-010611-134625 (2012).
- 1075102Droutman, V., Read, S. J. & Bechara, A. Revisiting the role of the insula in addiction. *Trends Cogn Sci*1076**19**, 414-420, doi:10.1016/j.tics.2015.05.005 (2015).
- 1077 Schimmelpfennig, J., Topczewski, J., Zajkowski, W. & Jankowiak-Siuda, K. The role of the salience 103 1078 affective deficits. network in cognitive and Front Hum Neurosci 17, 1133367, 1079 doi:10.3389/fnhum.2023.1133367 (2023).
- 1080104Moeller, S. J. & Goldstein, R. Z. Impaired self-awareness in human addiction: deficient attribution of1081personal relevance. *Trends Cogn Sci* **18**, 635-641, doi:10.1016/j.tics.2014.09.003 (2014).
- 105 Porrino, L. J., Smith, H. R., Nader, M. A. & Beveridge, T. J. The effects of cocaine: a shifting target over
 the course of addiction. *Prog Neuropsychopharmacol Biol Psychiatry* **31**, 1593-1600,
 doi:10.1016/j.pnpbp.2007.08.040 (2007).
- 1085106Manza, P. et al. Neural circuit selective for fast but not slow dopamine increases in drug reward. Nat1086Commun 14, 6408, doi:10.1038/s41467-023-41972-6 (2023).
- 1087 107 Lee, T. H., Kim, S. H., Katz, B. & Mather, M. The Decline in Intrinsic Connectivity Between the Salience
 1088 Network and Locus Coeruleus in Older Adults: Implications for Distractibility. *Front Aging Neurosci* 12,
 1089 2, doi:10.3389/fnagi.2020.00002 (2020).
- 1090108Song, J. *et al.* Age-related reorganizational changes in modularity and functional connectivity of human1091brain networks. *Brain Connect* **4**, 662-676, doi:10.1089/brain.2014.0286 (2014).
- 109109Fattore, L. *et al.* Astroglial in vivo response to cocaine in mouse dentate gyrus: a quantitative and1093qualitative analysis by confocal microscopy. *Neuroscience* **110**, 1-6, doi:10.1016/s0306-10944522(01)00598-x (2002).
- 1095110Dang, J. *et al.* Glial cell diversity and methamphetamine-induced neuroinflammation in human cerebral1096organoids. *Mol Psychiatry* **26**, 1194-1207, doi:10.1038/s41380-020-0676-x (2021).

- 1097111Nooner, K. B. *et al.* The NKI-Rockland Sample: A Model for Accelerating the Pace of Discovery Science1098in Psychiatry. *Front Neurosci* 6, 152, doi:10.3389/fnins.2012.00152 (2012).
- Shafto, M. A. *et al.* The Cambridge Centre for Ageing and Neuroscience (Cam-CAN) study protocol: a
 cross-sectional, lifespan, multidisciplinary examination of healthy cognitive ageing. *BMC Neurol* 14, 204,
 doi:10.1186/s12883-014-0204-1 (2014).
- 113 Owen, A. M., Downes, J. J., Sahakian, B. J., Polkey, C. E. & Robbins, T. W. Planning and spatial working
 1103 memory following frontal lobe lesions in man. *Neuropsychologia* 28, 1021-1034, doi:10.1016/00281104 3932(90)90137-d (1990).
- 1105 114 Hoffman, E. A. *et al.* Stress exposures, neurodevelopment and health measures in the ABCD study.
 1106 *Neurobiol Stress* 10, 100157, doi:10.1016/j.ynstr.2019.100157 (2019).
- 1107 115 Bernstein, D. P. & Fink, L. *Childhood Trauma Questionnaire: A Retrospective Self-report : Manual.*1108 (Psychological Corporation, 1998).
- 1109116McCarthy, S. *et al.* A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet* 48,11101279-1283, doi:10.1038/ng.3643 (2016).
- 1111 117 Desrivieres, S. *et al.* Single nucleotide polymorphism in the neuroplastin locus associates with cortical
 1112 thickness and intellectual ability in adolescents. *Mol Psychiatry* 20, 263-274, doi:10.1038/mp.2013.197
 1113 (2015).
- 1114 118 International HapMap, C. *et al.* Integrating common and rare genetic variation in diverse human 1115 populations. *Nature* **467**, 52-58, doi:10.1038/nature09298 (2010).
- 1116119Van Essen, D. C. *et al.* The WU-Minn Human Connectome Project: an overview. *Neuroimage* **80**, 62-111779, doi:10.1016/j.neuroimage.2013.05.041 (2013).
- 1118120Genomes Project, C. *et al.* A global reference for human genetic variation. *Nature* **526**, 68-74,1119doi:10.1038/nature15393 (2015).
- 1120121Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* 562, 203-1121209, doi:10.1038/s41586-018-0579-z (2018).
- 1122122Casey, B. J. *et al.* The Adolescent Brain Cognitive Development (ABCD) study: Imaging acquisition1123across 21 sites. *Dev Cogn Neurosci* **32**, 43-54, doi:10.1016/j.dcn.2018.03.001 (2018).
- 1124123Hagler, D. J., Jr. *et al.* Image processing and analysis methods for the Adolescent Brain Cognitive1125Development Study. *Neuroimage* 202, 116091, doi:10.1016/j.neuroimage.2019.116091 (2019).
- 1126124Schumann, G. *et al.* The IMAGEN study: reinforcement-related behaviour in normal brain function and1127psychopathology. *Mol Psychiatry* **15**, 1128-1139, doi:10.1038/mp.2010.4 (2010).
- 1128125Alfaro-Almagro, F. *et al.* Image processing and Quality Control for the first 10,000 brain imaging datasets1129from UK Biobank. *Neuroimage* **166**, 400-424, doi:10.1016/j.neuroimage.2017.10.034 (2018).
- 126 Taylor, J. R. *et al.* The Cambridge Centre for Ageing and Neuroscience (Cam-CAN) data repository:
 1131 Structural and functional MRI, MEG, and cognitive data from a cross-sectional adult lifespan sample.
 1132 *Neuroimage* 144, 262-269, doi:10.1016/j.neuroimage.2015.09.018 (2017).
- 1133 127 Salo, T. *et al.* NiMARE: Neuroimaging Meta-Analysis Research Environment. *NeuroLibre Reproducible* 1134 *Preprint Server* **1**, 7, doi:10.55458/neurolibre.00007 (2022).
- 1135 128 neurostuff/NiMARE: 0.0.11 v. 0.0.11 (Zenodo, 2022).
- 1136129Howe, L. J. *et al.* Within-sibship genome-wide association analyses decrease bias in estimates of direct1137genetic effects. Nat Genet 54, 581-592, doi:10.1038/s41588-022-01062-7 (2022).
- 1138130Zhao, B. & Zhu, H. On Genetic Correlation Estimation With Summary Statistics From Genome-Wide1139Association Studies. J Am Stat Assoc 117, 1-11, doi:10.1080/01621459.2021.1906684 (2022).
- 1140 131 Andreassen, O. A. et al. Improved detection of common variants associated with schizophrenia by

- 1141 leveraging pleiotropy with cardiovascular-disease risk factors. *Am J Hum Genet* **92**, 197-209, doi:10.1016/j.ajhg.2013.01.001 (2013).
- 1143
 132
 Xu, Y. *et al.* An atlas of genetic scores to predict multi-omic traits. *Nature* **616**, 123-131,

 1144
 doi:10.1038/s41586-023-05844-9 (2023).
- 1145
- 1146

1147 Acknowledgments

1148 We thank Professor Alexander S. Hatoum for providing the GWAS summary statistics of SUD risk factor. 1149 This work received support from the following sources: the General Projects of Shanghai Science and 1150 Technology Commission (21ZR1405000 [X.L.]), the National Nature Science Foundation of China [X.L.]), Key R&D Program of China (No.2018YFC1312904 [J.F.], 1151 (No.82304241 National 1152 No.2019YFA0709502 [J.F.] and No.2023YFE0199700[X.C.]), Shanghai Municipal Science and 1153 Technology Major Project (No.2018SHZDZX01 [J.F.], ZJ Lab [J.F.], and Shanghai Center for Brain Science 1154 and Brain-Inspired Technology [J.F.]), the 111 Project (No.B18015 [J.F.]), the China National Postdoctoral 1155 Program for Innovative Talents (BX20240086 [S.X.]), the Shanghai Yangfan Project (24YF2702200[S.X.]), 1156 the European Union-funded FP6 Integrated Project IMAGEN (Reinforcement-related behaviour in normal 1157 brain function and psychopathology) (LSHM-CT- 2007-037286 [G.S.]), the UK Research and Innovation (UKRI) funded UK government's Horizon Europe funding guarantee (10041392 and 10038599 [G.S.]), the 1158 1159 Horizon 2020 funded ERC Advanced Grant 'STRATIFY' ((Brain network based stratification of reinforcement-related disorders) (695313 [G.S.]), Human Brain Project (HBP SGA 2, 785907, and HBP 1160 SGA 3, 945539 [G.S.]), the Medical Research Council Grant 'c-VEDA' (Consortium on Vulnerability 1161 1162 Externalizing Disorders and Addictions) (MR/N000390/1 [G.S.]), the National Institute of Health (NIH) 1163 (R01DA049238 [G.S.], A decentralized macro and micro gene-by-environment interaction analysis of substance use behavior and its brain biomarkers), the National Institute for Health Research (NIHR) 1164 Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College 1165 1166 London, the Bundesministeriumfür Bildung und Forschung (BMBF grants 01GS08152; 01EV0711 [G.S.]; 1167 Forschungsnetz AERIAL 01EE1406A, 01EE1406B; Forschungsnetz IMAC-Mind 01GL1745B [G.S.]), the 1168 Deutsche Forschungsgemeinschaft (DFG grants SM 80/7-2, SFB 940, TRR 265, NE 1383/14-1 [G.S.]), 1169 the Medical Research Foundation and Medical Research Council (grants MR/R00465X/1 and MR/S020306/1 [S.D.]), the National Institutes of Health (NIH) funded ENIGMA (grants 5U54EB020403-05 1170 and 1R56AG058854-01 [S.D.]), NSFC grant 82150710554 and environMENTAL grant 101057429. Further 1171 1172 support was provided by grants from: - the ANR (ANR-12-SAMA-0004, AAPG2019 - GeBra [J.-L.M.]), the 1173 Eranet Neuron (AF12-NEUR0008-01 - WM2NA; and ANR-18-NEUR00002-01 - ADORe [J.-L.M.]), the 1174 Fondation de France (00081242 [J.-L.M.]), the Fondation pour la Recherche Médicale (DPA20140629802 1175 [J.-L.M.]), the Mission Interministérielle de Lutte-contre-les-Drogues-et-les-Conduites-Addictives 1176 (MILDECA [J.-L.M.]), the Assistance-Publique-Hôpitaux-de-Paris and INSERM (interface grant [M.-L.P.M.]), Paris Sud University IDEX 2012 [J.-L.M.], the Fondation de l'Avenir (grant AP-RM-17-013 [M.-1177 L.P.M.]), the Fédération pour la Recherche sur le Cerveau; the National Institutes of Health, Science 1178 Foundation Ireland (16/ERCD/3797 [R.W.]) and by NIH Consortium grant U54 EB020403 [S.D.], supported 1179 1180 by a cross-NIH alliance that funds Big Data Knowledge Centres of Excellence. ImagenPathways 1181 "Understanding the Interplay between Cultural, Biological and Subjective Factors in Drug Use Pathways" 1182 is a collaborative project supported by the European Research Area Network on Illicit Drugs (ERANID). 1183 This paper is based on independent research commissioned and funded in England by the National

1184 Institute for Health Research (NIHR) Policy Research Programme (project ref. PR-ST-0416-10001). The 1185 views expressed in this article are those of the authors and not necessarily those of the national funding 1186 agencies or ERANID. Data collection and sharing for this project was partly provided by CamCAN, funded 1187 by the UK Biotechnology and Biological Sciences Research Council (grant number BB/H008217/1), 1188 together with support from the UK Medical Research Council and University of Cambridge. The funders 1189 also had no role in study design, data collection and analysis, decision publish or preparation of the 1190 manuscript. The BRAINMINT study was supported by research grants from the Research Council of 1191 Norway (249795, 273345, 300767, 324499), the South-Eastern Norway Regional Health Authority (2014097, 2015073, 2016083, 2018076, 2019101), KG Jebsen Stiftelsen, the European Research Council 1192 1193 under the European Union's Horizon 2020 research and Innovation program (ERC StG Grant No. 802998), 1194 UiO:LifeScience (4MENT project), and the Department of Psychology, University of Oslo. Part of this work 1195 was performed on the TSD (Tjeneste for Sensitive Data) facilities, owned by the University of Oslo, 1196 operated and developed by the TSD service group at the University of Oslo, IT-Department (USIT; tsddrift@usit.uio.no), and using resources provided by UNINETT Sigma2 (#NS9666S) - the National 1197 1198 Infrastructure for High Performance Computing and Data Storage in Norway.

1199

1200 Contributions

1201 X.L., T.J., and J.F. conceptualized the study; R.S., X.L. and T.J. designed the analytic approach; R.S. 1202 analyzed the data and visualized the results; D.A. analyzed BrainMint datasets for validation; R.S., T.J. 1203 and X.L. wrote the manuscript; S.X. helped in preprocessing the neuroimaging and genetic data; T.W.R., 1204 B.J.S. and J.F. helped in interpreting the results; D.C., Z.C. helped in visualization; J.F., T.B., G.J.B., A.H. 1205 revised the draft; L.W. was the principal investigator of BrainMint study; T.B., G.J.B., A.L.W.B., S.D., H.F., 1206 A.G., H.G., P.G., A.H., J.-L.M., M.-L.P.M., E.A., F.N., D.P.O., L.P., S.H, M.N.S., N.V., H.W., R.W., and G.S. were the principal investigators of IMAGEN Consortium; Imaging, genetic and behavioral data in the 1207 1208 IMAGEN project were acquired and provided by the IMAGEN Consortium; All authors critically revised the 1209 manuscript. X.L., T.J., and J.F. contributed equally to this paper.

1210 Competing interests

1211 Dr Banaschewski served in an advisory or consultancy role for Lundbeck, Medice, Neurim Pharmaceuticals, Oberberg GmbH, Shire. He received conference support or speaker's fee by Lilly, 1212 1213 Medice, Novartis and Shire. He has been involved in clinical trials conducted by Shire & Viforpharma. He 1214 received royalties from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press. The present work is 1215 unrelated to the above grants and relationships. Dr Barker has received honoraria from General Electric 1216 Healthcare for teaching on scanner programming courses. Dr Poustka served in an advisory or 1217 consultancy role for Roche and Viforpharm and received speaker's fee by Shire. She received royalties 1218 from Hogrefe, Kohlhammer and Schattauer. The present work is unrelated to the above grants and 1219 relationships. The other authors report no biomedical financial interests or potential conflicts of interest.

1220

1221 Consortia

1222 IMAGEN Consortium

1223 Tobias Banaschewski^{7,8}, Gareth J. Barker⁹, Arun L.W. Bokde¹⁰, Sylvane Desrivières⁶, Herta Flor^{11,12}, Hugh 1224 Garavan¹³, Penny Gowland¹⁴, Antoine Grigis¹⁵, Andreas Heinz¹⁶, Jean-Luc Martinot^{17,18}, Marie-Laure

- Paillère Martinot^{17,18,19}, Eric Artiges^{17,18, 20}, Frauke Nees^{7,8,21}, Dimitri Papadopoulos Orfanos¹², Luise 1225 Poustka²², Michael N. Smolka²³, Sarah Hohmann^{7,8}, Nilakshi Vaidya²⁴, Henrik Walter¹⁶, Robert Whelan²⁵, 1226
- Gunter Schumann^{5,27} 1227



Fig. 1. Lifespan GMV trajectories for SUDs and HCs (A) Visualization of ROIs with significant differences between SUDs and HCs at different life stages throughout the lifespan. Blue indicates lower GMV in SUDs compared to HCs, while red indicates the opposite. (B) Estimated lifespan GMV trajectories for SUDs (red) and HCs (blue) with 95% confidence bands, adjusting for sex, handedness and study. Observed mean GMVs from each study were displayed as points, with errors bars representing standard errors (Top). Two sample t-test was used to compare GMV between SUDs and HCs across the lifespan, with Benjamini-Hochberg correction for multiple testing within each ROI. Log p-values from the tests were reported against the significance level (dashed red line) (Bottom).



Fig. 2. Comparison of behavioral and neurocognitive performances between SUDs and HCs. (A) Comparison of behavioral and neurocognitive performances between SUDs and HCs for all study cohorts, adjusting for sex, handedness and age. Two-tailed two-sample t-test was used, with BH-FDR correction for multiple testing within studies. CBCL, Child Behavior Checklist; BIS/BAS, Behavioral Activation and Behavioral Inhibition Scales; UPPS, Impulsive behavior scale; Flanker, Flanker Inhibitory Control and Attention Test; MID Monetary Incentive Delay task; S/LAR, small/large anticipated reward; SDQ, Strengths and Difficulties Questionnaire; TCI, Temperament and Character Inventory; SURPS, Substance Use Risk Profile Scale; KIRBY, Monetary-Choice Questionnaire; S/M/LDR, small/median/large delayed reward; ASR, Achenbach Adult Self Report; SSAGA, Semi-Structured Assessment for the Genetics of Alcoholism. *** $P_{adj}<0.001$; ** $P_{adj}<0.01$; * $P_{adj}<0.05$. (B) Volumetric differences between SUDs and HCs that can be explained by cognitive factors. Seven factors were extracted from 133 cognitive terms, and were named based on their first ten cognitive terms. Univariate linear regression was conducted between factor-level cognitive brain atlas and GMV differential patterns at each 0.5-year time interval. Triangles indicate positive-sided significance based on spin permutations of brain atlases, with BH-FDR method used for multiple testing. \blacktriangle : BH-FDR-corrected P<0.05; Δ : nominal P<0.05.



Fig. 3. Correlation between impulsivity/rule breaking scores and ROI centiles during pre-adulthood and adulthood. Distinct correlation patterns were observed in pre-adulthood (in ABCD and IMAGEN) and adulthood (in HCP). Impulsivity and rule breaking scores were obtained from factor anlaysis. Two-tailed t-test was used and BH-FDR method was used for multiple testing. IatOFC, lateral orbitofrontal; medOFC, medial orbitofrontal; ACC, anterior caudal cingulate; NAc, nucleus accumbens.



Fig. 4. Comparison of genomic differences between HCs and SUDs across studies. (A) Genetic correlations between genetic variants associated SUDs in different studies; Addrf, addiction risk factor. *** <0.001. (B) Flowchart of weighted GMV (wGMV) calculation. wGMV was calculated by weighting thee region of interest (ROI) centiles with z-values from the corresponding SUD differential regional patterns and could be interpreted as a brain score reflecting the likelihood of SUD. (C) Conjuctional False Discovery Rate (FDR) manhattan plot for SUDs and SUD-related brain score in ABCD, HCP and UKB/Addrf. One significant locus rs11609619 on chromosome 12 (mapped to *CCDC91*) was identified in ABCD. Three significant loci rs10936851 on chromosome 3 (mapped to *PTPRD*), rs9567983 on chromosome 13 (mapped to *NUDT15*) and rs6129798 on chromosome 20 (mapped to *ZHX3*) were identified in HCP. Additionally, one significant locus rs10438244 on chromosome 14 was identified in UKB/Addrf. (D) Cortical volumetric differences between SUDs and HCs explained by neurobiological markers and cortical microstructure markers. Dimensionality-reduced molecular brain atlase were obtained from Lotter et al.. **A** : BH-FDR-corrected *P*<0.05; Δ : nominal *P*<0.05.



Fig. 5. A panoramic view of dynamic changes in SUD encompassing brain structure, cognitive and behavioral performance, and genomic basis. The absolute overall brain difference in SUD across all ROIs was estimated by merging the p-values for cortical and subcortical differences and then converting the result into a Z statistic, while ignoring the directionality.